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Cardiovascular disease (CVD) is the leading cause of morbidity and mortality in
Western societies. The most important cause behind these diseases is a complex
condition affecting arterial blood vessels denoted as atherosclerosis. Atherosclerosis
is inflicted and restrained by lipoproteins circulating in blood. More specifically, high
levels of low density lipoprotein (LDL) have been found to correlate positively and
high levels of high density lipoprotein (HDL) inversely with the risk of atherosclerosis.
High LDL levels can be reduced by the use of statins, a strategy that has succes-
sively reduced the rate of CVD. However, a significant residual risk still remains since
atherosclerosis is a multifactorial disease. Because low HDL levels are an independent
risk factor, elevating HDL has become one the most promising strategies in the
fight against CVD. Clinical trials have shown that this can be achieved through the
inhibition of cholesteryl ester transfer protein (CETP), which transports neutral
lipids between different lipoprotein fractions. A novel molecular agent, anacetrapib,
has been found to meet these requirements but the precise inhibitory mechanism
remains to be elucidated.
In this study the interactions between CETP and anacetrapib were examined
using atomistic molecular dynamics simulations. Extensive structural and functional
analysis were performed for both particles. The obtained results point towards the
important regulatory roles of helix X and phospholipids during the lipid exchange
process. These structures were found to experience considerable conformational
fluctuations induced by the drug, indicating the possible capability of anacetrapib to
inhibit the functions of CETP.
The performed simulations are pioneering and pave the way for further studies,
with an objective to extend the scope of computational studies to gain a much deeper
understanding concerning the inhibition of CETP. The novel insight could be used
in the development of new molecular agents capable of preventing the progression of
CVD.
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Syda¨n- ja verisuonisairaudet ovat yleisin kuolinsyy teollisuusmaissa. Ta¨rkein tekija¨
na¨iden sairauksien taustalla on valtimonkovettumatauti, ateroskleroosi. Ateroskleroosi
on verenkiertoelimisto¨n toimintaan liittyva¨ sairaus, jonka ominaispiirteita¨ ovat koles-
terolin asteittainen kasautuminen seka¨ paikallisten ateroomaplakkien muodostuminen
verisuonten seina¨miin. Ateroskleroosin synnyssa¨ merkitta¨va¨ssa¨ roolissa ovat veren
lipoproteiinit. Kohonneen matalatiheyksisen lipoproteiinin (low density lipoprotein,
LDL) pitoisuuden uskotaan edista¨va¨n sairauden syntya¨, kun taas kohonneet kor-
keatiheyksisen lipoproteiinin (high density lipoprotein, HDL) pitoisuudet alentavat
sairastumisriskia¨.
Kohonnutta LDL-pitoisuutta voidaan alentaa statiineilla, jotka ovat yleisimmin
ma¨a¨ra¨ttyja¨ la¨a¨kkeita¨ ateroskleroosin hoidossa. Kuitenkin vain joka kolmannen poti-
laan kolesteroli alenee niiden avulla tavoitetasoon johtuen ateroskleroosin moniteki-
ja¨isyydesta¨. Koska matala HDL-pitoisuus on luokiteltu itsena¨iseksi riskitekija¨ksi, on
HDL-tason nostaminen yksi lupaavimmista tavoista syda¨n- ja verisuonisairauksien
ehka¨isemisessa¨. Kliiniset kokeet ovat osoittaneet, etta¨ ta¨ma¨ voidaan saavuttaa es-
ta¨ma¨lla¨ kolesteroliesterien siirta¨ja¨proteiinin (CETP) toimintaa. CETP:n toiminnan
esta¨miseen kehitetyn la¨a¨kkeen, anacetrapibin, on osoitettu vastaavan vaatimuksia.
La¨a¨kkeen tarkka esta¨mismekanismi on kuitenkin viela¨ selvitta¨ma¨tta¨.
Ta¨ma¨ tutkimus keskittyy CETP:n ja anacetrapibin va¨listen vuorovaikutusten
tutkimiseen molekyylidynamiikkasimulaatioiden avulla. Molempien molekyylien
rakennetta seka¨ toimintaa tutkitaan laaja-alaisesti. Tutkimustulokset korostavat
helix X:n seka¨ fosfolipidien ta¨rkea¨a¨ sa¨a¨televa¨a¨ roolia lipidien vaihdon aikana. Na¨iden
rakenteiden huomattiin uudelleenja¨rjesta¨ytyva¨n anacetrapibin vaikutuksesta, mika¨
viittaa la¨a¨kkeen kykyyn esta¨a¨ lipidien vaihtoa lipoproteiinien va¨lilla¨.
Tehdyt simulaatiot ovat laajuudessaan ensimma¨isia¨ ja siksi ne tarjoavatkin erino-
maiset la¨hto¨kohdat tuleville CETP:n toiminnan esta¨miseen liittyville tutkimuksille.
Na¨ita¨ tietoja voidaan ka¨ytta¨a¨ uusien, syda¨n- ja verisuonisairauksien etenemista¨
ehka¨isevien la¨a¨kkeiden kehityksessa¨.
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11. INTRODUCTION
Cardiovascular disease (CVD) is the leading cause of death in Western societies
covering all abnormal functions of the heart and blood vessels [1]. These diseases
cause incapacity for work, and in addition they also correspond to most of the costs
of the public health service. One of the risk factors behind these diseases is the
elevated level of low density lipoprotein cholesterol (LDL-C) in circulation. Low
density lipoprotein (LDL) particles transport cholesterol and its esters from the liver
to peripheral tissues where they are used as the building material of cell membranes
and for the production of hormones, vitamin D and bile acids [2]. However, the excess
transportation of LDL-C is followed by a complex series of events affecting arterial
blood vessels, leading to a condition called atherosclerosis, which is the underlying
and the most important cause behind different CVDs [1]. Hence LDL particles are
often denoted as ”bad cholesterol”. The early stage of an atherosclerotic plaque
forms when LDLs accumulated in the arterial intima become oxidized and altered
in other ways. As a consequence, an inflammatory response is stimulated that fuels
the progression of atherosclerosis, eventually leading to formation of atherosclerotic
plaques. This gives rise to the narrowing of arteries, rupture of the plaque, clotting,
and finally a potential death.
Another plasma lipoprotein denoted as the high density lipoprotein (HDL) pos-
sesses important antiatherogenic functionalities. It transports cholesterol from the
opposite direction compared with LDL, that is, from peripheral tissues into the
liver to be excreted and recycled [2]. Due to this, HDL is denoted as ”good choles-
terol”. Up to date, the most sensitive indicator of CVDs is the relation of LDL-C
to HDL-cholesterol (HDL-C). If it is not in accordance with general guidelines
(< 3.5 mmol/dL), it eventually leads to the accumulation of LDL particles into arte-
rial wall [3]. In the biggest risk are those who have elevated LDL-C level, decreased
HDL-C level, an unhealthy way of life and obesity or genetic genotype for CVDs.
Since the formation of an atherosclerotic plaque takes decades to develop into a
phase where vessel narrowing causes clinical complications, better ways of detecting
the disease are needed. Several clinical trials have shown that cholesterol-lowering
medication effectively reduces the risk of atherosclerosis since the lipoproteins have a
significant role in the formation of the plaques [1, 4]. These novel molecular agents
have been developed in order to provide everybody with equal possibilities to lower
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the levels of cholesterol and, more specifically, to lower the level of LDL-C and to
increase the level of HDL-C. These levels can be influenced also with healthy ways of
life such as reducing alcohol consumption, cutting down on smoking and following a
versatile physical exercise and diet.
In the past decade, lowering the level of LDL-C has been the major target in
the prevention of cardiovascular events. This approach has proven to be beneficial
and effective for both the primary and secondary prevention of CVDs since nume-
rous useful drugs, such as statins, have been developed. However, a large portion
of cardiovascular events cannot be prevented by LDL-C lowering strategies since
atherosclerosis is a multifactorial disease. Because low levels of HDL have been
identified as an independent risk factor, elevating HDL levels has become one of the
most promising strategies in the fight against CVDs. Hence the search for finding
even better treatment methods is more and more focusing on HDL.
Several clinical trials have shown that the inhibition of cholesteryl ester transfer
protein (CETP) increases the level of HDL-C in the human bloodstream. CETP is
a plasma protein that transports cholesteryl esters (CEs) and triglycerides (TGs)
between HDL and other lipoprotein particles. As a consequence, HDL is catabolised
more rapidly and cholesterol is transported mainly via LDL [5]. Therefore a promising
strategy for reducing the risk of CVDs is to develop novel molecular agents that
inhibit the lipid transfer functions of this protein. This is not a straightforward issue
concerning drug development since the first developed drug, torcetrapib, increased
the HDL-C level as was hoped but it also increased the blood pressure as well as the
mortality rate [6]. Due to this, all the clinical trials concerning torcetrapib had to be
terminated. The development of the drug continued and a real breakthrough was
published at the end of the year 2010 when a new variant of the drug, anacetrapib,
was found to inhibit CETP without severe cardiovascular events [7].
Despite these promising achievements, the precise mechanism of how this drug
inhibits the functions of CETP remains unknown. In addition, the relationship
between the inhibition and increases in HDL-C levels is yet to be proven. Therefore
the ultimate purpose of this work is to study the interactions between CETP and
anacetrapib and to gain more detailed information in this regard. The aim is to tie
the observed findings with the inhibitory mechanism of the drug. The interactions
are studied using atomistic molecular dynamics (MD) simulations which offer a
possibility to examine small scale particles with detailed knowledge on an atomic
scale. The performed simulations are pioneering and serve as a solid foundation
for future studies concerning the interactions of the whole HDL-CETP-anacetrapib
complex. The obtained results can be used for the development of new molecular
agents in the fight against the generation and progression of CVDs.
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This work is divided into six chapters. The next chapter discusses the biological
background relevant to this work, describing the connection between atherosclerosis,
levels of cholesterol, inhibition of CETP and anacetrapib. The molecular structures
of CETP and anacetrapib are presented in depth. The third chapter explains the
classical molecular dynamics method in detail, with an emphasis on the force field
and the ensembles used to describe the physical conditions. The fourth chapter
contains the initial configurations of the simulated systems as well as the parameters
applied in the simulations. In addition, it lists the methods used to analyze the
obtained data. The chosen methods are commonly used to analyze the changes
in the structure and functions of proteins. The fifth chapter presents the results
obtained from the simulations and discusses their physical importance. Finally, the
conclusions summarize the results and present ways of how this research can be used
in future studies.
42. BIOLOGICAL BACKGROUND
In this chapter, the biological background relevant to this thesis is discussed. First
are reviewed the formation and progression of atherosclerosis as a complex form of
CVD as well as the role of plasma lipoproteins in this process. Next the structure
and role of CETP in the transportation of CEs and TGs between different lipoprotein
fractions are discussed. Inhibiting the lipid transfer functions of this protein increases
the level of HDL-C and decreases the level of LDL-C in human blood plasma, thus
correlating with a reduced risk of CVDs. Inhibition can be obtained through the use
of novel molecular agents, and hence anacetrapib is presented as one possible CETP
inhibitor.
2.1 Relevance of cardiovascular diseases
CVDs encompass all abnormal functions of the heart and blood vessels and are
among the leading causes of death and disease both in Finland and in other western
countries [1]. In addition to causing incapacity to work, CVDs are responsible for a
great deal of the costs of the public health service. The underlying and the most
important cause behind these diseases is atherosclerosis, a multifactorial disease,
which narrows the arteries as a cause of cholesterol build up and formation of an
atherosclerotic plaque. This prevents the flow of blood to deliver oxygen to tissues
and may finally lead to plaque rupture, clotting and potential death. Atherosclerosis
develops in the course of several years and has usually proceeded far before the first
symptoms appear. Therefore it is important to pay attention to the development of
different treatment methods in order to reduce the risk of CVDs.
2.1.1 Cardiovascular diseases in general
The group of CVDs can be divided into the ischaemic heart diseases, cerebrovascular
diseases and diseases of the arteries as presented in table 2.1 [1]. The most general
symptoms of CVDs include the myocardial infarction (heart attack), heart failure,
cerebral infarction (stroke) and cardiac rhythm problems [8]. The probability of
these cardiovascular events to occur increases with multiple risk factors since they
reinforce each other in their influence on morbidity and mortality. This leads to the
reduction of the quality of life and life expectancy.
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Table 2.1: Cardiovascular diseases. Modified from [1].
Ischaemic heart diseases Cerebrovascular diseases Diseases of arteries
Angina pectoris Cerebral infarction Atherosclerosis
Acute myocardial infarction Aortic aneurysm
Subsequent myocardial infarction Arterial embolism
Chronic ischaemic heart disease Arterial thrombosis
The diagnosis, care and follow-up of several risk factors play a central role in
the prevention and care of CVDs. The risk factors include different environmental,
biochemical and genetic risk factors, see table 2.2 [8, 9]. These factors can be divided
into preventable and unpreventable risk factors. The factors that can be prevented
or treated include alcohol consumption, smoking, physical inactivity, diet, obesity,
diabetes, high blood pressure and levels of cholesterol. The unpreventable risks
include the appearance of CVDs in the family, gender and age. The heritability of
CVDs has been shown in many family and twin studies [4].
Table 2.2: Risk factors for cardiovascular disease. [1, 4]
Risk factor Environmental Physiological Genetic
or biochemical
Alcohol consumption x x
Smoking x x
Lack of physical activity x x
Diet x x
Obesity, body composition x x
Diabetes and blood glucose levels x x
Hypertension x x
Low HDL levels x x
High LDL levels x x
High triglyceride levels x x
Thrombotic factors x x
Family history of CVD x x
Male gender x
Age x
The most important risk factor is the elevated level of cholesterol in circulation
which is a consequence of the amount and function of the plasma lipoproteins [4].
It has been shown that atypical levels of lipoproteins are a prerequisite for most
forms of CVDs. In the group of the biggest risk are those who have elevated levels
of LDL-C as well as reduced levels of HDL-C. The general guidelines for these
levels are < 3 mmol/L and > 1 mmol/L, respectively, as well as < 5 mmol/L for
the total cholesterol level [3]. If the cholesterol levels are consistent with these
2. Biological background 6
recommendations, it helps to keep the heart healthy.
Healthy lifestyle including the cutting down on excessive alcohol consumption and
smoking, as well as versatile physical exercise and diet are essential parts of the basic
care of CVDs. With the help of sufficient physical exercise the risk of coronary artery
disease can be prevented and, in addition, it also has positive effects concerning
the reduction of obesity and the diseases associated with it such as the high blood
pressure [8, 10]. Healthy and versatile diet lowers the levels of cholesterol when the
intake of saturated fat as well as the consumption of sugary and processed foods
are avoided [10, 11]. In addition, the diet does not cause costs comparable with
medication. Another approach to lower the cholesterol levels is to use pharmacological
agents that reduce the production of cholesterol in the liver or reduce the absorption
of cholesterol when the removal of cholesterol from tissues increases [12]. Furthermore,
the elevated cholesterol content of blood can be reduced with the help of agents
which prevent the absorption of bile acids (e.g. resins and guarkumi) or with agents
that prevent the formation of fats (e.g nicotinic acid and its derivatives) [12].
The clinical data from multiple trials have demonstrated that in the primary
and secondary prevention of cardiovascular events the 3-hydroxy-3-methylglutaryl
coenzyme A (HMG-CoA) reductase inhibitors, statins, are the most effective agents
to reduce the level of LDL-C [11, 13]. The effect of statins is based on the inhibition of
the HMG-CoA reductase when the synthesis of cholesterol in the liver is prevented [14].
As a consequence, the number of LDL-receptors of liver cells increases and LDL-C is
transported from the circulation into the liver [15]. Thus the levels of total cholesterol
and LDL-C decrease by 25 % to 55 % depending on the agent and dose. Statins are
well tolerated medicines. They have been reported to have so-called pleitropic effects,
which include the reduction of oxidative stress and vascular inflammation as well
as the improvement of the stability of atherosclerotic plaque [16, 17]. The clinical
importance of pleitropic effects is still unclear but they have inspired researchers to
look for new applications for statins.
Despite their life saving aspect, a significant residual risk of cardiovascular events is
still apparent under statin therapy. This is because atherosclerosis is a multifactorial
disease and the current medication is not enough to prevent the progression of CVDs.
Since low levels of HDL have been identified as an independent risk factor, also
the therapy concerning the elevation of HDL-C levels has to be improved. Clinical
trials concerning this issue have involved the use of niacin, cholesterylamine and
fibrates [10, 11, 18]. Niacin has been shown to increase the HDL-C levels by 15-35 %
through inhibiting the secretion of very low density lipoprotein (VLDL) particles,
increasing the lipoprotein lipase activity and decreasing the TG levels [19]. Fibrates
(e.g. gemfibrozil) have been shown to raise the levels of HDL-C by 10-15 % through
the hepatic expression of the main HDL apolipoproteins A-I and A-II (apoA-I and
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apoA-II) [19, 20]. These results are promising, yet there still is a strong need to
develop even more efficient therapies. One strategy to meet these requirements is to
use CETP inhibitors which are a novel way to lower the levels of HDL-C, see Section
2.3 for further details.
2.1.2 Atherosclerosis
CVDs such as the heart disease and stroke usually result from a complex series
of events affecting arterial blood vessels leading eventually to a condition called
atherosclerosis [1]. This disease is usually denoted as atherosclerotic cardiovascular
disease (ASCVD) whose severity can be predicted from the risk factors listed at
table 2.2 [21]. Popular descriptions concerning ASCVD suggest that cholesterol
gradually builds up on the surface of passive vessel walls [2]. The formed plaque
eventually closes off the affected vessel if it grows large enough, thus preventing blood
from flowing. If tissue sustains lack of oxygen, it dies causing a stroke or heart attack.
As recently as two decades ago, scientists have proposed that cholesterol accumulates
within the vessel walls where its components become oxidized and altered in other
ways. The altered components stimulate an inflammatory response that fuels the
development of ASCVD [2].
The structure of the normal healthy artery is presented in the first cross section
in Figure 2.1. The artery consists of three morphologically distinct layers denoted
as the intima, the media and the adventitia. The normal intima is a thin region of
the vessel wall closest to the bloodstream, consisting of a connective tissue matrix
of proteoglycans and collagen [4]. It is the essential layer concerning the generation
of atherosclerosis since the early stage of an atherosclerotic plaque forms when
excess LDL-C starts to accumulate within the intima, see the cross section two. In
addition to its detrimental effects, cholesterol is needed as the building material of cell
membranes and to the production of hormones, vitamin D and bile acids [22]. After
accumulation, the lipids as well as the proteins composing LDL particles undergo
oxidation [23]. The altered components lead endothelial- and smooth muscle cells
to secrete chemicals which attract inflammatory cells to attach to the vessel wall
and to multiply and mature into active macrophages. Macrophages, also denoted as
foam cells, take up the extensively modified lipid particles with the help of various
receptors and ligands, see the cross section three [2].
HDL particles are also carried from the circulation into the intima. They are
smaller in size than LDLs and do not bind to the extracellular matrix composed of
proteoglycans. When HDLs meet foam cells, cholesterol that resides in them starts
to flow into HDLs [24]. This is followed by the HDL-mediated cholesterol transport
back to the liver thus defining the antiatherogenic role of these particles. If modified
LDLs are formed in the intima more than HDLs are able to remove, cholesterol
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Figure 2.1: The formation of an atherosclerotic plaque. The longitudinal section of the
artery (top) depicts the timeline of the initiation and the progression of
atherosclerosis from normal artery (1) to atherosclerotic plaque (5, 6, 7). The
cross sections of the artery (bottom) describe the evolution of the plaque.
See text for further details. Modified from [14].
starts to accumulate also outside the cells [24]. As a result, the chemicals secreted
by the endothelial cells attract white blood cells into the intima. The white blood
cells together with the foamy macrophages produce many inflammatory mediators
that amplify the inflammatory activities in the vessel walls and, as a consequence,
atherosclerotic plaque starts to develop [2, 13].
The inflammatory activities change the character of the vessel wall, generating a
bigger and more complicated plaque with a fibrous cap over the lipid core, see the cross
section four in Figure 2.1. The cap increases the size of the plaque but additionally
separates it out from the blood. The integrity of the cap depends on collagen fibers
made by the smooth muscle cells which can be degraded by the enzymes secreted
by macrophages [13]. If the weakened plaque ruptures as presented in the cross
section five, blood encounters the lipid core with proteins able to make the blood to
coagulate causing a clot [2]. If the clot is big enough, it will prevent the flow of blood
to the heart causing a heart attack, thrombus or stroke. The cross sections six and
seven present a healing response caused by the products associated with thrombosis.
The healing process leads to an increased collagen accumulation and a growth of
smooth muscle cells which can produce the symptoms of stable chest pain [14].
Recently, several clinical studies have suggested a different approach for the
formation of the plaque. These studies have reported that the formation of the
plaque is more related to the pile up of calcium carbonate on the vessel walls. This
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calcification is followed by an inlammatory response fuelled by the accumulation of
excess cholesterol. It has been noticed that vitamin D has a central role in this process
as well as the fact that there is a link between vitamin D deficiency and the different
risk factors of CVDs [25, 26]. Several mechanisms explain the reasons behind this link.
First, low levels of vitamin D increase the levels of the parathyroid hormone which in
turn increases the risk of inflammation [27]. Second, the supplementation of vitamin
D may down-regulate the serum markers of inflammation [26, 27]. However, more
clinical studies are needed to confirm these issues but undoubtedly the formation of
atherosclerosis is a very complex process.
Despite the controversial suggestions, the plaque formation takes decades to
develop into a phase where vessel narrowing causes clinical complications. Due to
this, better ways of detecting ASCVD are needed since narrowed coronary arteries
are not able to supply enough blood and oxygen to the heart. In addition to healthy
lifestyle, several clinical trials have shown that lipid lowering medication reduces the
risk of ASCVDs by reducing the cholesterol production of liver or by lowering the
absorption of cholesterol due to the significant role of lipoproteins in the formation
of plaques.
2.1.3 Lipoproteins
Lipoproteins, the water-soluble colloidal particles transporting insoluble lipids within
the human bloodstream [28], are among the most studied structures in biology. The
most important reason behind this interest is the crucial role of lipoproteins in the
emergence and treatment of different CVDs. However, the understanding about the
precise molecular structures and functions of lipoproteins in the nanometer length
scales have been a challenging task, but the development of MD simulation methods
and computing power has offered added value for the research of lipoproteins over
the nanometer length scales as well as over the microsecond time scales.
Lipoproteins are lipid-protein complexes that can be divided into different fractions
based on their density. These fractions are denoted from the most sparse to the densest
as chylomicrons, VLDL, intermediate density lipoprotein (IDL), LDL and HDL, as
presented in table 2.3 [24]. Each particle contains a different amount of phospholipids
(PL), unesterified cholesterol (UC), TGs, CEs and specific apolipoproteins bound
onto the surface of lipoproteins. From these the PLs, UC and apolipoproteins form
an amphiphilic monolayer that surrounds a hydrophobic core consisting of TGs and
CEs [24]. The apolipoproteins originate in the liver and intestines and regulate
the dynamic processes of lipoprotein assembly by binding to specific enzymes or
transport proteins on the cell membranes, thus directing the lipoprotein to the proper
site of metabolism [28]. These transfer proteins are called CETP and phospholipid
transfer protein (PLTP), which modify the composition of lipoproteins through
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neutral lipid transfer [24]. CETP transports TGs, CEs and PLs between lipoproteins
whereas PLTP transports only PLs [24]. In addition to size, density and lipid-protein
composition, the lipoprotein particles differ from each other also in regard to their
individual functions in metabolism.
Table 2.3: Lipoproteins and their composition. The size, the density, the major
apolipoproteins and the percentage values of PLs, TGs and CEs are pre-
sented [10, 19, 24, 28, 29].
Chylomicrons VLDL IDL LDL HDL
Size (nm) 100-500 30-90 25-50 18-28 5-15
Density (g/mL) < 0.93 0.93-1.006 1.006 1.019 1.063
-1.019 -1.063 -1.210
Apolipoproteins B-48, C-II, E B-100, E, C-II B-100, E B-100 A-I, A-II
PLs (%) 8 20 22 29 46
TGs (%) 85 50 31 13 5
CEs (%) 3 18 29 50 40
Except for LDL and IDL, all lipoprotein particles are synthesized in the liver. The
chylomicrons and VLDL particles transport mainly TGs from the liver to peripheral
tissues for utilization [28]. The primary function of HDL and LDL particles is the
transportation of cholesterol and its esters in the bloodstream. More specifically,
LDL particles transport cholesterol from the liver to peripheral tissues whereas HDL
particles transport it from the opposite direction from tissues into the liver to be
recycled or excreted [24]. IDL is similar to LDL and it transports both TGs and
cholesterol [28].
Low density lipoprotein
LDL is a spherical particle presented in Figure 2.2. The hydrophilic monolayer
consists of PL components called phosphatidylcholine and sphingomyelin and a single
copy of apolipoprotein B-100 (apoB-100) drawn as dark blue, light blue and grey,
respectively [30]. The apoB-100 has an important role together with receptors and
different enzymes to maintain the structural integrity and to control the interactions
of LDL particles [30]. The hydrophobic lipid core is comprised of TGs and CEs
drawn as green and yellow. Both the monolayer and the core contain UC drawn as
red.
Although the composition and overall structure of LDL particles are well known,
the experiments done to obtain information on the interactions between the surface
and core components have led to contradictory results [30, 31]. Due to this, the
model of LDL comprising the surface monolayer and the lipid core have not been
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Figure 2.2: Schematic representation of the LDL particle. The molecular components
are drawn with different colours: phosphatidylcholines as dark blue, sphin-
gomyelins as light blue, TGs as green, CEs as yellow, UC as red and apoB-100
as grey. Modified from [30].
accurate enough, and therefore a new model has been introduced. Hevonoja et al.
[30] described LDL with a three-layer model where the LDL particle has been divided
into three radially dissimilar structural layers named as the outer surface layer, the
interfacial layer and the core [30]. The outer surface layer consists of PL headgroups
whereas the interfacial layer consists of interdigitating core and surface lipids [30].
The pure core consists of molecules that are not in the direct contact with the surface
monolayer. The apoB-100 have parts in each of these three layers [30]. However,
Murtola et al. [31] found that the distribution as well as the ordering of the lipids in
the LDL particle are rather complex, thus suggesting that the three-layer model is
inadequate to describe the properties of lipids in LDL particles [31]. Hence additional
studies are needed to understand the structural as well as dynamical properties of
LDL particles.
LDL as well as IDL particles are not synthesized in the liver as the other lipoprotein
particles, but instead the formation of these particles occur during the VLDL
metabolism. In this chain reaction VLDLs are first hydrolyzed into IDLs which
are then converted into LDL [24]. When the VLDL mediated TG particles enter
the capillaries of peripheral tissues they come into contact with lipoprotein lipase,
hepatic lipase and endothelial lipase. These components together with an activating
protein, apolipoprotein CIII on the VLDL surface, hydrolyze TGs and release fatty
2. Biological background 12
acids for tissue utilization [19, 32]. Due to this, the TG content of VLDL is reduced
thus inducing this particle to convert into IDL. Part of IDLs are removed by the
liver and part are converted into LDL during a process where a hepatic lipase further
degrades the TGs inside IDL [19, 32].
LDL particles are the key players in cholesterol transport and metabolism because
they are the main carriers of cholesterol in circulation. They transport cholesterol
from the liver and intestines to other tissues which use it to repair the membranes
or to produce steroids [2, 33]. In addition, LDLs transport vitamins and hormones
to various cell types [33]. Despite these fundamental functions, LDL possesses also
detrimental effects. One of these is the excessive transportation and accumulation
of cholesterol in the intima which promotes the generation of ASCVDs. Due to
this, LDL is often called ”bad cholesterol”. The relationship between LDL-C and
ASCVDs has been established through several animal models and clinical investi-
gations. High LDL levels can be reduced by the use of statins, a strategy that has
successively reduced the rate of cardiovascular events. Despite the use of these agents,
a significant residual risk remains since nearly two-thirds of cardiovascular events
continue to occur [18, 20]. Therefore the focus has shifted beyond LDL-C lowering
to include therapies that increase the levels of HDL-C. Indeed, several clinical trials
have authenticated the proposal that increased HDL-C levels correlate with a reduced
risk of ASCVDs [34, 35].
High density lipoprotein
High density lipoprotein is a CE-rich particle characterized by the smallest size and
the highest density of the plasma lipoproteins, see table 2.3. The structure presented
in Figure 2.3 is similar with the structure of LDL despite that HDLs a constitute
remarkably heterogeneous group differing in density, size, lipid composition and
apolipoprotein content. Due to this, HDL particles can be fractionated into five
subclasses ranging from small, dense HDL3c, HDL3b and HDL3a to larger HDL2a,
HDL2b and discoidal pre-β HDL [36]. The main apolipoproteins of HDL are apoA-I
and apoA-II having amphiphilic alphahelical structures that help them to attach
to the surface of the lipid matrix [37]. These apolipoproteins are required for the
efficient cholesterol eﬄux from macrophages as well as to regulate the transportation
of lipids into and out of cells [38]. In addition, HDL contains several other proteins
and enzymes of which lecithin-cholesterol acyltransferase (LCAT) has an important
role in cholesterol esterification [10, 37].
The main function of HDL is the transportation of cholesterol and its esters from
tissues to the blood circulation and liver for recycling or excretion. Approximately
one third of the cholesterol transport is mediated through HDL. Based on this
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Figure 2.3: Schematic representation of the HDL particle. The molecular components
are drawn with different colours: PL headgroups and hydrocarbon chains as
dark and light gray, CEs as orange, TG as green and UC as yellow. Modified
from [39].
anti-atherogenic function, HDL is often called ”good cholesterol”. The transportation
of cholesterol occurs through a process called reverse cholesterol transport (RCT)
presented in Figure 2.4 [10]. In general this process involves the acceptance of cellular
lipids by HDL, the exchange of lipids between different lipoproteins and HDL and the
final delivery of the lipids to the liver for excretion [18, 28]. The size and composition
of HDL depends on these different metabolic steps.
When presented in more detail, the process of RCT involves the circulation of lipid-
poor HDL particles containing apoA-I and apoA-II. These particles are lipidated with
PLs and UC in a process which depends on the adenosine triphosphate (ATP)-binding
cassette A1 (ABCA1), see the step one in Figure 2.4 [11, 28]. After lipidation the
apolipoproteins form discoidal HDL particles which acquire UC from other lipoprotein
particles. The LCAT enzyme esterifies these cholesterol molecules producing CEs
when the shape of HDL particles converts from discoidal into spherical as presented
in the step two [11, 28]. The composition and shape of HDLs are further modified by
CETP which transfers CEs from HDL to LDL and VLDL particles in exchange for
TGs. VLDL and LDL then transport CEs to the liver via the LDL-receptor pathway
or they are taken up by the liver via the scavenger receptor class B member 1 (SR-B1)
pathway presented in the step three [18]. TGs transported to HDL are hydrolyzed
by hepatic lipase regenerating small and discoidal HDL particles thus restarting the
cycle [41]. According to this, the route of RCT occurs mainly through LDL and
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Figure 2.4: Reverse cholesterol transport of cholesterol mediated by HDL. The steps
marked as numbers describe the different phases of the process. See text for
further details. Modified from [40].
VLDL and partly through HDL. However, if the pro-atherogenic LDL transports
cholesterol to tissues more than LCAT is able to esterify, build up of cholesterol
begins within the arterial intima [41]. These different metabolic steps have been
studied also via MD simulations and the role of simulations has been remarkable
during the last decade. Several studies have clarified the molecular structure and
functions of HDL involved in RCT. See references [39, 40, 42–46] for further details
and discussion.
Besides the essential role of HDL in RCT, it has been proposed to have an-
tioxidant, antithrombotic, pro-fibrinolytic and anti-inflammatory properties against
ASCVDs [18]. Since LDL particles undergo the oxidative modification within the
arterial intima, the capability of HDL to inhibit this modification is potentially
anti-atherogenic. The inhibition can be achieved through the antioxidant or an-
tithrombotic protection mechanisms. The antioxidant property is due to the inhibi-
tion of the transmigration of monocytes and the cytotoxicity induced by oxidised
LDLs [4, 10, 11]. In the antithrombotic protection mechanism HDL transports
several platelet-activating factors that eventually break down the oxidized LDLs and
neutralize their proinflammatory effects [11, 17, 47]. The activation of C reactive
protein (CRP) due to the production of pro-inflammatory cytokines also plays an
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important role in the antithrombotic protection mechanism since this protein is a
marker of inflammation [2]. The main action of CRP is to activate complement and
to counteract infections [48]. In addition, HDL inhibits the inflammatory mediator
cytokine through a process involving an HDL-mediated inhibition of endothelial cell
sphingosine kinase [10]. This process is called the anti-inflammatory mechanism and
it is influenced by the PL composition of HDL [10]. However, the exact inhibitory
mechanisms of these diverse biological mechanisms to atheroprotective effects of HDL
remain uncertain, thus further investigations are needed.
As mentioned earlier, during the last decades the research in order to reduce
ASCVDs has concentrated on the reduction of the level of LDL-C. Despite the
development of numerous useful drugs, ASCVDs continue to be the leading cause of
death and disease worldwide and therefore the goal is to find and develop even better
treatment methods. The level of HDL-C has been established to be an independent
risk factor for these diseases and therefore the studies concentrate more and more
on HDL. In addition to the mechanisms of fibrates and niacin, inhibition of CETP
has been identified to increase the HDL-C level in the blood. Hence one strategy to
reduce ASCVDs is to develop novel molecular agents that inhibit the lipid transfer
functions of this protein.
2.2 Cholesteryl ester transfer protein
The connection between the role of CETP and the level of HDL-C was noticed for
the first time in Japan in 1989 where in several cases a human genetic deficiency
of CETP was related to elevated levels of HDL-C [49, 50]. These studies indicate
the inhibition of CETP to be anti-atherogenic. However, some mutation phenotypes
suggested increased ASCVD risk based on the ability of CETP to transport CEs
from antiatherogenic HDL to proatheronic VLDL and LDL in exchange for TGs [51].
This leads to TG enrichment in HDL as well as to enhanced deposition of cholesterol
on the arterial wall [52, 53]. TG enrichment is harmful to HDL since it results in
a loss of apoA-I and reduction in size leading to increased catabolism of HDL [53].
Hence CETP can theoretically be considered either antiatherogenic or proatherogenic.
This complex relationship gave rise to studies to define the regions of CETP that are
important in function through the production of monoclonal antibodies to inhibit
the lipid transportation mechanism [54, 55]. In addition, several animal models and
early clinical trials have indicated the proatherogenic role of CETP, thus supporting
the view that inhibition is a promising strategy for achieving higher levels of HDL-C
and lower the risk of severe cardiovascular events [2, 18].
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2.2.1 Molecular structure
The human CETP gene exists as a single copy in chromosome 16 in the 16q12-21
region [56]. The gene is expressed at high levels in adipose tissue and the liver [36].
The crystal structure of CETP has been solved by Qiu et al. [55]. Based on that
model, CETP is a 472-residue long hydrophobic glycoprotein shaped like a boomerang
with dimensions of 13.5 nm x 3 nm x 3.5 nm, see Figure 2.5. The structure can
be divided into four units: one terminal at each end of the protein (terminals N
and C), a central β-sheet as a linker between the two terminals and a distorted
amphipathic helix named helix X, containing the amino acids Glu461-Ser472 at the
C terminal domain [55]. Each terminal contains a twisted β-sheet and two helices. In
the figure, the helices are denoted A and B in terminal N, and A’ and B’ in terminal
C, with helices B and B’ being longer than A and A’. The central β-sheet includes
six antiparallel strands consisting of residues before and after the terminals.
Linker
Helix X
A
A’
B
B’
Ω2
Ω1
N-terminal C-terminal
Figure 2.5: Crystal structure of human CETP. The four structural units shown are the
terminals N and C, central β-sheet as a linker between the terminals and
helix X. Helix X belongs to the C-terminal domain but interacts with residues
of the N-terminal domain. Helices A, A’, B and B’ as well as the loop regions
Ω1 and Ω2 are labeled. CEs are drawn as cyan space fills of cholesteryl oleate
molecules and PLs as red bonds. Modified from [57].
CETP has a 6-nm-long lipid filled tunnel that traverses the core of the molecule
and has two distinct openings. The openings are plugged by PLs called dioleoylphos-
phatidylcholine (DOPC) molecules presented as red bonds in Figure 2.5. DOPCs
(DOPC1 and DOPC2) bury their acyl chains inside the hydrophobic tunnel and
expose the zwitterionic head groups to solvent [55]. As the binding mode of DOPCs
is like this, they shelter the hydrophobic moieties and allow the protein to be more
compatible with the aqueous environment. CETP has two neutral lipid binding sites
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located inside the tunnel for binding either two CEs, one CE and one TG or two
TGs [55]. The figure presents the protein carrying two CE molecules (CE1 and CE2)
drawn as cyan space fills buried in the middle of the tunnel. CE1 is located between
the terminal N and the central β-sheet whereas the site for CE2 resides between the
central β-sheet and terminal C. Therefore the lipids fill the length of the tunnel and
bind in the same orientation with the head of CE2 packed against the tail of CE1.
The tunnel is formed by a wall of β-sheets underneath the bound lipids and a layer
of helices above the lipids [55]. The cross-sectional areas of both openings and the
dimensions of the tunnel are large enough to allow the passage of a neutral lipid.
The helix X is located at the C-terminal domain but the hydrophobic face interacts
with DOPC1 of the N-terminal domain forming an apolar path to neutral lipid access
to the tunnel [55]. The increased B-factor of helix X suggests that the structure of
the helix is mobile, Hisb462-Leu464 being a potential hinge region for movements [55].
The B-factor is also known as the atomic displacement parameter and in the protein
crystal structure it indicates the fluctuation of an atom about its average position [58].
Therefore, the higher the B-factor, the higher the mobility of an atom in question.
Another regions of increased B-factors include the loop regions marked as Ω1 (residues
284-316) and Ω2 (residues 346-356) in Figure 2.5 [55]. Helix X has been proposed to
act as a lid conducting the neutral lipid exchange by alternating its open and closed
states [55, 59]. This is discussed in detail in the next section.
The structure of the concave surface of CETP has been found to be able to bind to
lipoprotein surfaces with different curvatures with the modest movements of helix X
and the loop region Ω1 [55, 60]. Other surfaces of CETP do not have the proper
curvature to bind spherical lipoproteins and they lack the direct access to the tunnel
thus supporting the concept that the concave surface is the only one able to bind
lipoproteins. The inherent curvature of CETP makes it well suited to bind HDL-sized
particles through its charged and tryptophan residues, indicating the importance of
electrostatic interactions during binding [59, 61]. In order to match the curvatures of
larger lipoproteins, conformational changes in the structure of the protein occurs.
It has been shown that the major part of CETP is associated with HDLs since the
affinity of CETP to bind HDL is higher compared with plasma LDL or VLDL [5].
The formation of the CETP-lipoprotein complex is suggested to be modulated by
pH, surface pressure and the introduction of positive divalent ions such as Ca2+ and
Mn2+ into the solution [61, 62].
2.2.2 Function
The main function of CETP is to transport and exchange neutral lipids between
HDL and other lipoprotein fractions. CETP transports CEs from HDL to VLDL
and LDL and TGs in the opposite direction [55]. In addition, CETP transports
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also PLs between these particles [18]. Two different mechanisms for the transfer
of lipids have been proposed [63]. The ternary complex model suggests that the
transfer occurs within a temporary complex between CETP and two lipoproteins [63].
However, the concave surface of CETP indicates that it can bind only one lipoprotein
at a time, thus suggesting that the protein operates by a carrier mechanism. First
a neutral lipid is accepted from a donor particle to the hydrophobic tunnel, then
it is transported through the aqueous phase and finally delivered to an acceptor
lipoprotein. The carrier mechanism can occur either through a homoexchange or a
heteroexchange mechanism. In homoexchange, CETP applies bidirectional transfer
of the same neutral lipid whereas in the more physiologically relevant heteroexchange
it transfers different lipids between the lipoprotein particles. The heteroexchange
suggests, that when a neutral lipid is accepted by the acceptor particle, CETP cannot
detach from the surface of a lipoprotein without acquiring another neutral lipid [60].
In addition, PLs are needed to refill the tunnel openings in order for CETP to be
compatible with the aqueous environment [55]. Koivuniemi et al. [59] found in their
study that the structure of CETP is unstable without the interior lipids since the
hydrophobic tunnel collapsed when CEs were removed from the structure. This
finding suggests that the tunnel is not empty at any point during the lipid exchange.
CETP mediates the homoexchange mechanism for PLs although the net exchange of
these molecules is mainly carried out by the PLTP [55].
The heteroexchange transportation mechanism is part of RCT and therefore CETP
plays a central role in lipoprotein metabolism [64]. The route of RCT and the activity
of CETP related to this process are presented in Figure 2.6 including the presence of
normal as well as increased activities and the absence of CETP. The initial step is
the transportation of dietary cholesterol to peripheral tissues through LDL. Excessive
cholesterol is removed by HDL with the help of LCAT, which provides the driving
force for the removal of cholesterol. The rate of lipid transfer between different
lipoprotein particles is influenced by an increased TG level, eventually resulting CE
depletion and TG enrichment in HDL [65]. Combined activities of CETP and hepatic
lipase induce the formation of smaller dense HDL particles that are more rapidly
catabolised [5, 65]. Due to this, the route of RCT occurs mainly via LDL and VLDL
which eventually are taken up by the liver via SR-B1. As long as this process to
remove LDL and VLDL stays normal, these particles do not accumulate excessively
into the intima. However, during the increased activity of CETP the rate of CE
transportation to LDL and VLDL is increased leading to a reduction in the size of
HDLs as well as to their increased catabolism [53]. Consequently, CE-enriched LDL
particles accumulate in the intima. Increased CETP activity is caused by increased
CETP gene expression in peripheral tissues or increased concentrations of acceptor
lipoproteins [5].
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Figure 2.6: Models of RCT and the related activity of CETP in three different metabolic
settings. a) RCT in the presence of normal CETP activity. b) RCT when the
activity of CETP is increased. c) RCT in the absence of CETP in humans
with genetic CETP deficiency. See text for further details. Drawn using [5]
as a reference.
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During the deficiency of CETP, all its neutral lipid transfer functions are absent.
Therefore the content of TGs is decreased and the content of CEs is increased in
HDL particles. Because of this and the continued activity of LCAT, HDL particles
gradually increase in size and acquire apolipoprotein E, thus becoming a high affinity
ligand for the LDL receptors of the liver. These receptors eventually remove the
increased HDL particles and, moreover, also the cholesterol from tissues [5]. The
absence of CETP results in a build up of HDL to very high levels and thus the amount
of cholesterol transported in VLDL and LDL is reduced [66]. Due to these facts
the deficiency of CETP correlates with reduced risk of ASCVDs. The mechanism
of CETP inhibition to raise the HDL-C level is suggested to occur through the
stimulation of cholesterol eﬄux and anti-inflammatory effects in macrophage foam
cells [67]. Therefore the route of RCT is changed to occur through HDL instead of
VLDL and LDL.
It has been proposed that during lipoprotein binding the PLs plugging the openings
of the hydrophobic tunnel may merge into the PL monolayer of lipoprotein to permit
the access of neutral lipids into the tunnel [55]. In addition, helix X has been
suggested to move aside from the N-terminal opening, thus facilitating the lipid
exchange [60]. Based on the MD simulations performed by Koivuniemi et al. [59],
it was shown that during binding the PLs migrated away from the tunnel openings
forming a small hydrophobic patch under the concave surface of CETP. In addition,
these simulations showed that the conformation of helix X rearranged and became
buried inside the hydrophobic tunnel instead of the PL monolayer [59]. According to
these observations helix X is claimed to play a central role in the process of neutral
lipid exchange. It is suggested to act as a lid, conducting the lipid exchange, being
locked to the open state for the time of exchange and to the closed state during lipid
transfer. Therefore there are two important functional properties of the helix that
make the lipid exchange possible: management of the lipid exchange by opening
the hydrophobic pathway from a lipoprotein surface to the hydrophobic tunnel and
the improvement of the diffusion of neutral lipids from the hydrophobic tunnel to
lipoproteins by filling the volume of CETP-bound neutral lipid when it diffuses out
from CETP [59].
According to the given suggestions, the movement of helix X aside from the
N-terminal tunnel opening is considered to be sufficient for the lipid exchange to
occur. However, this is in contradiction with several mutational studies that showed
that when helix X was completely removed from the structure of CETP, the protein
was able to exchange only PLs but not CEs or TGs [68, 69]. For this reason the role
of helix X may not be as simple as previously suggested. Instead, it is probable that
it interacts according to a currently unknown mechanism with CEs, thus facilitating
their exchange, but the confirmation of this issue requires further research.
2. Biological background 21
In any case, the conformational changes of helix X can be considered to have
an important role in the inhibition of CETP. One possible strategy to achieve the
inhibition is the development of nonpolar drugs that are then transferred into the
hydrophobic tunnel of CETP. Based on MD simulations done by Koivuniemi et al.
[59] it can be assumed that helix X is locked to the open state when inhibitors
are bound to CETP. This may be due to the fact that the inhibitor changes the
conformational distribution of helix X to favor the open state. This would stabilize
the CETP-HDL complex since CETP would not be able to detach from the surface of
HDL without helix X to shield the hydrophobic tunnel opening. In addition, CETP
may not be able to bind and transport PLs since either the open state or the drugs
could prevent the binding of PLs to the C-terminal opening thus further stabilizing
the complex.
2.3 Inhibitors of cholesteryl ester transfer protein
The most promising strategy up to date to increase the HDL-C level is to inhibit
the lipid transfer functions of CETP. This can be achieved through the use of novel
molecular agents which, depending on the inhibitory mechanism, prevent either
the binding of neutral lipids or their release once bound or initiate the excessive or
insufficient binding of CETP to lipoproteins. As these diverse inhibitory actions
suggest, the precise mechanism requires further elucidation. This work attempts
to clarify this issue behind the novel agent anacetrapib, which has been shown to
effectively raise the HDL-C level with an acceptable side effect profile in patients
with ASCVDs or risk factors for ASCVDs [7]. Understanding the functions of CETP
as well as the mechanisms behind CETP inhibitors are important to realize in order
to develop safe treatment methods for the pharmacological raising of HDL-C.
2.3.1 Anacetrapib
Structure-activity relationship
Anacetrapib, previously denoted as MK-0859, is an orally active, potent and se-
lective CETP inhibitor developed to treat ASCVDs. It was identified by high-
throughput screening to belong to the 1-3-oxazolidin-2-one series of CETP in-
hibitors developed by Merck [70]. The chemical name of the agent is denoted
as (4S,5R)-5-[3,5-bis(trifluoromethyl)phenyl]-3-[4’-fluoro-2’-methoxy-5’-(propan-2-yl)-
4-(trifluoromethyl)[1,1’-biphenyl]-2-yl]methyl-4-methyl-1, 3-oxazolidin-2-one and the
molecular formula is C30H25F10NO3 [71]. The structural formulas of all the current
CETP inhibitors anacetrapib, torcetrapib and dalcetrapib are presented in Figure 2.7.
As can be seen from Figure 2.7, anacetrapib shares some structural similarities
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Figure 2.7: Structural formulas of different CETP inhibitors. Drawn using [71] as a
reference.
with torcetrapib but is different from dalcetrapib. Anacetrapib consists of three
aromatic biphenyl (C6H5) rings connected with a 2-oxazolidinone ring (C3H5NO2). In
addition, it has three trifluoromethyl (CF3) groups as well as three methylene (CH3)
groups connected to its biphenyl rings. The biggest differences between anacetrapib
and the other two inhibitors are the absence of the 2-oxazolidinone group from both
torcetrapib and dalcetrapib as well as the absence of trifluoromethyl groups from
dalcetrapib. It has been reported that modifications of the oxazolidinone ring led to
the discovery of anacetrapib [72]. The medicinal chemistry behind this discovery is
described in [72].
Both anacetrapib and torcetrapib have been reported to increase the binding
affinity of CETP towards lipoproteins and to induce a tight reversible binding making
the HDL-CETP complex more stable [70, 73]. This mechanism of action differs from
the one performed by dalcetrapib which forms an irreversible disulfide bond with the
cysteine at residue 13 of CETP [74]. The increased binding has been shown to inhibit
the CETP-mediated cholesterol exchange between lipoproteins. The potency of
anacetrapib to inhibit the transfer of CEs described with the half maximal inhibitory
concentration (IC50) has been shown to be 17± 4.8 nM with similar values for the
transfer of TGs [75]. Torcetrapib has the similar inhibitory potencies of CEs and
TGs compared with anacetrapib, whereas dalcetrapib has a 70- to 80-fold weaker
potency (IC50 = 1178 ± 443 nM) [75]. This indicates that anacetrapib is at the
moment the most promising agent to increase HDL-C.
The activity of anacetrapib has been studied using pharmacokinetics and phar-
macodynamics. This is performed by investigating the absorption, distribution,
metabolism and excretion profiles of anacetrapib in a single oral dose study on
humans [76]. The results of this in vitro study suggested that anacetrapib probably
applies a low-to-moderate degree of oral absorption later supported by the pharma-
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cokinetics study of anacetrapib in rats and rhesus monkeys [77]. It was found out
that the absorbed fraction of the dose is metabolized mainly via CYP3A4-catalyzed
oxidative metabolism followed by the excretion of three oxidative metabolites through
the biliary-fecal route [76]. CYP3A is an enzyme common to the metabolism of
a number of drugs, e.g. statins, used in the treatment of ASCVDs [78]. The
three metabolites of anacetrapib excreted during the process of metabolism involved
O-demethylation which was further hydroxylated at the biphenyl and isopropyl moi-
eties [76, 77]. The finding concerning the metabolism and clearance of anacetrapib
was further supported by the clinical drug-drug interaction study, which investigated
whether anacetrapib is an inducer or an inhibitor for the CYP3A activity. The study
showed that catabolism of anacetrapib does not seem to interfere with other drugs
metabolized through the CYP3A4 pathway [78]. In addition, anacetrapib was found
to stay intact after metabolism and due to these facts, the oxidative metabolism
can be considered as the major route of eliminating anacetrapib from the blood
circulation [76]. In general anacetrapib is a well-tolerated agent but the long-term
safety and tolerability of the drug remains to be evaluated.
The corresponding profiles of torcetrapib were compared with the profiles of anace-
trapib. The comparison revealed significant differences between the metabolism and
the routes of elimination of these two inhibitors. A total of 15 primary and secondary
metabolites of torcetrapib were identified in humans and these were eliminated mainly
through urinary excretion [76]. This difference is suggested to be related with the
differences in the metabolic pathways of the agents. As anacetrapib applies the oxida-
tive metabolism, the key feature in the metabolism of torcetrapib was reported to be
related with an oxidative cleavage [76]. This induces the formation of low-molecular
weight metabolites including quinaldic acid and bistrifluoromethylbenzoic acid which
were excreted via the renal pathway [76].
Clinical trials
The ability of anacetrapib to increase the level of HDL-C as well as to decrease
the level of LDL-C related to the inhibition of the lipid transfer functions of CETP
has been studied in phase one, two and three clinical trials performed in humans.
The early phase one trial involved patients with dyslipidaemia as well as healthy
individuals receiving either anacetrapib or placebo. The effect of anacetrapib on
lipoprotein levels was studied from the dyslipidaemic patients and the effect on blood
pressure was examined from the healthy participants. The results were promising
since a 129 % increase in HDL-C and a 38 % decrease in LDL-C were documented in
patients with dyslipidaemia and no effect on blood pressure was observed with healthy
individuals [79]. Similar increases in lipoprotein cholesterol levels were observed in
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a phase two study where 589 patients with dyslipidaemia were randomly assigned
to anacetrapib. Results showed up to 139 % increase in HDL-C and up to 40 %
decrease in LDL-C without an effect on blood pressure [80].
Determining the Efficacy and Tolerability of CETP Inhibition With Anacetrapib
(DEFINE)-trial recruited 1623 patients with coronary heart disease or at high risk
for coronary heart disease already receiving statin therapy for an anacetrapib phase
three trial [81]. The patients were divided into two groups from which one received
anacetrapib and the other a matching placebo. After one and a half years, the
level of LDL-C had reduced from 2.1 mmol/dL to 1.2 mmol/dL in the anacetrapib
group whereas the corresponding numbers in the placebo group were decreased from
2.1 mmol/dL to 2.0 mmol/dL. This means a 39.8 % reduction in the anacetrapib
group when compared with the placebo group. Correspondingly, the level of HDL-C
had increased from 1.0 mmol/dL to 2.6 mmol/dL in the anacetrapib group, compared
with an increase from 1.0 mmol/dL to 1.2 mmol/dL in the placebo group - a 138.1 %
greater increase in the anacetrapib group. Therefore the cholesterol values obtained
in the anacetrapib group corresponded well with the general guidelines presented
in Section 2.1.1. The apoB level decreased by 21 % and apoA-I level increased by
44.7 % in the anacetrapib group beyond the changes seen in the placebo group,
thus indicating that the overall effects of anacetrapib on the cholesterol levels are
two to four times as large as those with other CETP inhibitors tested until now.
Anacetrapib was also stated to have an acceptable side-effect profile since changes in
the blood pressure or at the levels of aldosterone and electrolytes were not observed
in comparison with torcetrapib.
Despite the promising results, concerns have been raised whether the larger,
cholesterol-rich HDL particles generated through CETP inhibition remain antiathero-
genic. These concerns have been defused by the investigations of HDL particles
isolated from patients treated with torcetrapib and anacetrapib. It has been shown
that these HDL particles promote even enhanced RCT and cholesterol eﬄux from
macrophages [82, 83] through the ATP-binding cassette subfamily G (ABCG)-
transporter [11, 67]. The higher the level of HDL-C, the more enhanced these
functions are.
2.3.2 Other inhibitors
Torcetrapib
The first developed CETP inhibitor was torcetrapib (4-[(3,5-Bis-trifluoromethylbenzyl)-
methoxycarbonyl-amino]-2-ethyl-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1- car-
boxylic acid ethyl ester). In the early small phase one studies torcetrapib was shown
to increase the level of HDL-C from 6 % to 91 % and to decrease the level of
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LDL-C from 21 % to 42 % in healthy subjects and patients with HDL-C less than
2.2 mmol/dL [84, 85]. In addition, these trials showed that the level of apoA-I was
elevated and the level of apoB was reduced.
Torcetrapib was evaluated on a much larger scale through the Investigation
of Lipid Level Management to Understand its Impact in Atherosclerotic Events
(ILLUMINATE)-trial. 15067 patients with a history of ASCVD were assigned to this
randomized, double-blind trial [6]. The patients were divided into two groups, one
received torcetrapib plus atorvastatin whereas the other received only atorvastatin.
During the 18-month-study the patients receiving torcetrapib experienced a 72.1 %
increase in HDL-C and a 24.9 % decrease in LDL-C [6]. The changes in the cholesterol
levels were shown to be caused by the ability of torcetrapib to promote the formation
of CETP-lipoprotein complex thus blocking both neutral and PL transfer activities
of CETP [66]. However, ILLUMINATE trial was prematurely terminated because of
an increase in mortality and morbidity caused by cancers and infections. Torcetrapib
was shown to increase the blood pressure of 3-6 mmHg, decrease the serum potassium
level and increase the levels of serum sodium, bicarbonate and aldosterone [6]. The
possible causes for the failure of torcetrapib are these off-target effects together with
an adverse effect of CETP inhibition in the generation of dysfunctional HDL particles
not participating in RCT [86, 87].
The effects of torcetrapib on the progression of coronary atherosclerosis, carotid
atherosclerosis in familial hypercholesterolemia and carotid intima-media thickness
in mixed dyslipidaemia were studied in The Investigation of Lipid Level Manage-
ment Using Coronary Ultrasound to Assess Reduction of Atherosclerosis by CETP
Inhibition and HDL Elevation (ILLUSTRATE) [86], in the Rating Atherosclerotic
Disease Change by Imaging With a New CETP Inhibitor 1 (RADIANCE 1) [88] and
in the RADIANCE 2 [87] trials, respectively. Despite the elevated HDL-C level and
reduced LDL-C level observed in all these trials, torcetrapib was not stated to reduce
the progression of any of these diseases. In addition, in every trial torcetrapib was
associated with an increase in blood pressure similar with the ILLUMINATE trial.
The relationship of these lipid changes and progression of coronary atherosclerosis
was studied in the post hoc analysis and it was observed that the patients with
the greatest HDL-C increase did have some regression of the disease caused by the
modest increase in the eﬄux of cholesterol from macrophages into HDL [82, 89].
Despite these controversial results, it may be concluded that the generated HDL
particles are functional and participate in RCT. This indicates that the concept of
CETP inhibition to protect against ASCVDs remains viable and thus the failure of
torcetrapib was related to the molecule rather than the mechanism of action.
The reasons behind the lethal side effects caused by torcetrapib has been explained
through the interactions of the drug with unknown off-targets since CETP inhibitors
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have been suggested to bind several proteins leading to the observed side effects [90].
This protein-ligand network can be identified using the approach denoted as chemical
systems biology. The approach systematically explores the interactions between pro-
teins and the ligand incorporating them into biological pathways [90]. This provides
valuable information about the molecular mechanisms behind the side-effect profile
of torcetrapib. The identified off-targets were reported to belong to different protein
families but they are structurally and functionally related to CETP [90]. These
proteins are mainly involved in the lipid metabolism, immune response and signaling
networks. It is suggested that the number of side-effects caused by torcetrapib can be
minimized by fine tuning the multiple off-target interactions by introducing molecules
that bind to those molecular components that are involved in the regulation of
negative metabolism [90].
Dalcetrapib
Dalcetrapib, also known as JTT-705, is a thioester S-(2-((1-(2-ethylbutyl)cyclohexane)
carbonylamino)phenyl)2-methylpropanethioate [91]. It is the only competing inhibitor
for anacetrapib currently on the market. Dalcetrapib has been reported to bind
covalently to CETP by forming a disulphide bond with cysteine 13 locating inside
the hydrophobic tunnel of CETP [74]. This bond formation is suggested to be the
essential requirement for the dalcetrapib-mediated CETP inhibition since it induces a
conformational change in the structure of CETP, which could increase the stability of
HDL-CETP complex [65, 75]. Therefore, in addition to the binding mode, differences
exist also in the inhibitory mechanism when comparing dalcetrapib with torcetrapib
and anacetrapib. However, more investigations are needed in order to better compare
the different inhibitors with each other.
In the early study dalcetrapib was shown to increase the level of HDL-C and to
inhibit the progression of atherosclerosis in cholesterol-fed rabbits [74]. However, in
rabbits with more severe hypercholesterolemia, dalcetrapib did not reduce the risk of
atherosclerosis despite increases in HDL-C [92]. Despite these controversial results,
dalcetrapib increased HDL-C up to 34 % and decreased the activity of CETP by 37 %
in healthy patients with mild hyperlipidemia in a randomized phase two study [93].
Another phase two study involving patients with dyslipideamia on pravastatin therapy
showed 28 % increase in HDL-C and a 30 % decrease in CETP activity [94]. Neither of
these studies showed an increase in blood pressure or adverse cardiovascular events, as
seen in the trials concerning torcetrapib. These findings were supported in the safety
and tolerability trial of dalcetrapib [95]. Currently a phase three clinical trial with
15600 coronary syndrome-patients concerning dalcetrapib’s effects on cardiovascular
morbidity and mortality is ongoing [96]. It is estimated to be completed in 2012 [92].
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3. MOLECULAR DYNAMICS
In this thesis, the interactions between CETP and anacetrapib are studied with
classical MD simulations. These simulations are a computer aided way to calculate
the movements and interactions of systems consisting of several small particles using
classical mechanics. Compared with experimental measurements, the MD simulations
have many advantages but also disadvantages. Understanding these is important in
order to interpret the obtained results accurately and correctly. This chapter gives
an overview of the MD simulation method applied in this study. The overview is
based mostly on the manual of the applied software, GROMACS [97], since it gives
a solid description of MD.
3.1 The classical molecular dynamics method
The real life experiments and MD simulations have many similarities with each other
despite the fact that the experiments are performed in a laboratory and the MD
simulations on computers. An experiment begins with a sample preparation followed
by the actual tests and measurements. In order to reduce the random statistical noise
and the possibility of measurement errors more samples are prepared, measured and
averaged. In a similar manner, the MD simulation is started by first constructing the
system to be simulated with a topology and a force field describing the structures of
particles and the interactions between them. After this, the system is equilibrated
from an initial configuration consisting of the initial coordinates and velocities of the
system. This is done by using Newton’s equations of motion. After equilibration,
the simulation can be started.
One major disadvantage of experimental measurements is that they are difficult to
perform in small scales - in nanoscales this is almost impossible. Hence one solution to
study the behavior of small particles is to use MD simulations. They offer a possibility
to examine the small scales with detailed knowledge on an atomic scale. The second
significant advantage of MD simulations is their cheap implementation. The primary
disadvantages are the inaccuracy and the small sizes of the systems to be modeled.
Both of these problems are mainly caused by the large computational need required
by the totally atomistic MD simulations. Even though the modern calculation units
consist of several thousands of processor cores, models used to simplify the description
of interactions and movements of systems over irrelevant details must be developed.
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With the help of these models it is possible to approximate and combine different
things, and in this way the computation time will be considerably shortened.
Additionally also the time scales of biological processes compared with the time
scales of simulations are a source of problems. Essentially the problem is caused
by the fact that the modeling methods currently available are not able to operate
both reliably and efficiently over long time scales. As an example, the so called ab
initio-methods allow a very detailed examination of a particle over a scale smaller
than the atomic one. These methods take the quantum-mechanical nature of the
particle into consideration, but the calculations are computationally very heavy and
the studied systems very small. A good example is the folding problem of proteins
with different sizes. The folding of small proteins from the open structure towards
the equilibrium state takes at least one microsecond. By using the ab initio-methods,
these transformations can be studied only up to a few picoseconds and a single
computer requires approximately one year for the calculation. Hence in order to
understand the comprehensive operation of a biological system, other methods have
to be considered. One solution is to use classical mechanics which neglects the
quantum mechanics. The time needed in calculations is shorter and hence the
systems can be larger. Summarizing, the understanding of biological systems requires
the exploitation of all the different modeling approaches.
As mentioned, the MD simulation begins with creating an initial structure for
the system to be simulated and giving the required parameters for the simulation.
Every simulated particle is simply thought of as a center of mass to which the
interactions are directed from the force field and the potential functions related to it.
The core of MD simulation is a loop where the force field is used to calculate the
forces interacting between the particles, and according to these, the positions and
velocities of each particle are updated using Newton’s equations of motion. The loop
is repeated with a regular interval until enough simulation data has been gathered.
In addition, the simulation is assumed to follow the ergodic hypothesis meaning
that the time average of the system is equivalent to the ensemble average of the
system. However, before the MD simulations could have been invented and utilized
in different studies, investigations concerning the molecules forming the biological
world and their structures have been carried out. The formation of a constantly
developing and freely available molecule databank provides wide opportunities for
biomolecular modeling.
3.2 Structure of the molecule
The field of biomolecular modeling dates back to the 1960s and nowadays it is
developing rapidly. Advances are driven by improvements in computing power,
memory capabilities, algorithms for molecular dynamics as well as the developing
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and versatile genomic and structural databases. The first records of crystallized
polypeptides and proteins date to the end of the 1920’s and the beginning of the
1930’s [98]. The techniques to clarify the crystal structures more carefully developed
further and in late 1950’s the first x-ray diffraction pattern from the crystal structure
of a protein was obtained. Structure determination based on x-ray crystallography
involves the analysis and comparison of the x-ray diffraction pattern of a native
protein to those associated with the protein bound to heavy atoms like mercury [98].
Another important technique for solving biomolecular structures is nuclear magnetic
resonance spectroscopy. With the help of this method it is possible to obtain
information about the interactions and the localized motions of the molecules [98].
With the aid of protein crystallization techniques it has been possible to relate the
structural information of a system to its functions. It is known that proteins play
crucial roles as constituent molecules and as triggers of physiological processes for all
living things. Proteins for instance provide the support in muscle tissues, ligaments,
tendons, bones and organs. They also play crucial regulatory roles in transport and
storage, such as oxygen in muscle and blood cells. Moreover, the proteins make the
moving, signal transmission and immuno defence of cells possible. Protein itself is
an organic compound consisting of amino acids linked together as a chain. Amino
acids bond themselves to each other with peptide (N-C) bonds. Each amino acid
consists of a central tetrahedral carbon known as the alpha carbon (Cα) attached to
a hydrogen atom, a protonated amino group (NH+3 ), a dissociated carboxyl group
(COO−) and a varying side chain [98]. There are 20 naturally occuring amino acids
of which humans can synthesize about a dozen thus leaving the remaining amino
acids to be ingested through the diet.
The structure of a protein can be classified with four basic levels: primary structure
(the sequence of amino acids), secondary structure (regular local structural patterns
such as α-helices and β-sheets), tertiary structure (the three-dimensional arrangement
of all atoms in the protein in space) and quarternary structure (the complete 3D
interaction network) [98]. Most proteins adopt a specific 3D conformation which is
related to their biological activities. The conformations of proteins are composed
of four secondary structural elements, namely the α-helices, β-sheets, turns and
loops. The classical right-handed α-helix connects each backbone carbonyl (C=O)
oxygen of residue i to the backbone hydrogen of the NH-group of residue i + 4
and therefore the helix has 3.6 residues per turn [98]. The helix may be curved
depending on the amino acid sequence. 310- and pi-helices are common variants of the
α-helix motif and they are usually unstable in solution. 310-helix is tighter compared
with the α-helix since it has 3 residues per turn involving hydrogen bonds between
residues i and i+ 3 [98]. The nomenclature reflects that there are 10 atoms within
the hydrogen bond. pi-helix in turn is more loosely coiled having hydrogen bonds
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between residues i and i + 5 [98]. Other helix types are left-handed α-helix and
collagen helix. The second basic element is the β-sheet which forms by aggregating
amino acid strands (β-strands) via hydrogen bonds [98]. β-strands are 5-10 residues
long and the aggregation can occur in a parallel or anti-parallel orientation. Turns
can be found in regions where the sharp reversals of orientation reside, such as in
the junction between two parallel β-strands whereas loops occur in short regions
connecting various motifs [98]. The majority of these elements lie on the surface
of the protein because of the solvation considerations, since most loops are highly
hydrophilic and interact with solvent [98].
The structure of a biomolecule, as obtained from the x-ray crystallography, is still
insufficient for the proper understanding of its functions and biological activity, since
it only provides a frozen view of a complex system. In addition, attention should be
paid to how well the x-ray structure describes the protein in its native environment,
because the x-ray structure may include packing effects. Molecules are members
of living matter whose constituent atoms continuously interact with each other as
well as with their surroundings. At this point the MD simulations join the picture
since the molecular conformation, motion and the associated biological functions of
different molecules can be studied with the help of simulations. In this way it is
possible to connect the structure of a complex system to its functions.
3.3 Topology
Every MD simulation requires a molecular description of the particles to be simulated.
The description is called a topology and it contains the size and shape as well as
the complete description of all the interactions that occur within and between the
particles in the simulated system [99]. One commonly applied method - and the one
applied in this study - is to produce a topology for a system, which includes every
atom in the description. If the simulations need to be faster, it is possible to use a
united-atom representation where the number of atoms is decreased by representing
methyl and methylene groups as a single particle [99]. The process to simplify the
description is called coarse graining but it is not discussed here further.
With the help of molecule databanks providing information about experimentally-
determined structures of proteins, nucleic acids and other complex assemblies, it
is possible to easily achieve the topology of a molecule. However, when there
does not exist a ready topology, it has to be constructed. The construction is
not always a straightforward process since it may require a manual placing of
particles to their desired positions, and afterwards the energy minimization of
this artificial structure to remove the steric clashes and inappropriate positions
of atoms. How this is done depends on the system under study. Neither is the
parametrization of a particle straightforward since this process begins with the
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considerations of intramolecular potential energies and atomic partial charges through
quantum mechanical calculations. These are then held fixed while the non-nonded
interactions are determined. The results are compared with experimental data and
the parameters are adjusted if needed.
3.4 Force field
The interactions between different particles are described through a force field. The
interactions can be divided into bonded and non-bonded. Bonded interactions
describe the interactions between particles connected by a chemical bond, including
the stretching of the bond and the bending of the bond angle and dihedral angle. Non-
bonded interactions desribe the interactions between any pair of particles including
the weak van der Waals-type and electrostatic Coulombic forces. These interactions
are pair-additive and centro-symmetric in the MD software (GROMACS) applied in
this study. The terms of the mathematical equations describing the interactions are
derived from both experimental work and high-level quantum mechanical calculations.
3.4.1 Bonded interactions
The bonded interactions include not only the interactions between two atoms but also
the 3- and 4-body interactions. 2-body interactions are denoted as bond stretching,
3-body interactions as bond angle and 4-body interactions as dihedral angle. The
bond stretching between two covalently bonded atoms i and j can be described by a
harmonic potential
Vb(rij) =
1
2
kbij(rij − bij)2, (3.1)
where kij is the force constant describing the rigidity of the bond, rij is the distance
between the particles and bij is the reference distance.
The bond angle vibration between a triplet of atoms i− j − k is represented with
a similar manner as the bond distance vibrations, namely using a harmonic potential
on the angle θijk:
Va(θijk) =
1
2
kθijk(θijk − θ0ijk)2, (3.2)
where θijk is the angle between the three atoms, kijk is the force constant and θ
0
ijk is
the reference angle.
A proper dihedral angle describes the angle between two planes formed by four
particles. These angles can either be periodic or of the Ryckaert-Belleman -type and
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they are defined according to IUPAC/IUB convention where φ is the angle between
the planes ijk and jkl. Zero angle corresponds to the cis configuration which means
that i and l are on the same side. The dihedral interaction can be described as
Vd(φijkl) = kφ(1 + cos(nφijkl − φs)), (3.3)
in which φijkl is the angle between the four atoms, kφ is the force constant, n is a
selectable constant and φs is the reference angle. Improper dihedral is a special type
of dihedral interaction used to force the atoms to remain in a plane or to prevent
transition to a mirror image.
3.4.2 Non-bonded interactions
The non-bonded interactions usually contain a repulsion term, a dispersion term and
a Coulomb term. The repulsion and dispersion terms are combined in terms of the
weak van der Waals interactions described by the Lennard-Jones (LJ) potential:
VLJ(rij) = 4ij
((
σij
rij
)12
−
(
σij
rij
)6)
, (3.4)
where rij describes the distance between the particles i and j. The parameters ij
and σij are chosen separately for each pair of particles. ij describes the minimum
energy of the potential well and σij describes the distance when the potential changes
from repulsive to attractive.
The classical Coulombic potential describes the electrostatic interactions between
two charged particles:
VC(rij) =
1
4pi0r
qiqj
rij
, (3.5)
where 0 is the permittivity in vacuum and r the relative permittivity. q is the
charge of the particle in question.
3.5 Equations of motion
The molecular dynamics approach is simple in principle. We simulate motion of a
system under the influence of a specific force field by following molecular configurations
in time according to Newton’s equations of motion for a system consisting of N
interacting atoms with positions {ri} and masses {mi}:
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mi
∂2ri
∂t2
= Fi, i = 1...N. (3.6)
The total force, Fi, acting on a particle i is the negative derivative of a potential
function V (r1, r2, ..., rN):
Fi = −∂V
∂ri
(3.7)
These two equations are solved simultaneously in small time steps. The most time-
consuming part of a MD simulation is the computation of the forces in the system.
In order to minimize the amount of computation, the forces acting on a certain
particle are calculated only for a certain group of neighbour atoms that lie within the
cut-off radius for the interaction. The information of which interactions to calculate
is contained in the neighbour lists.
In order to calculate new coordinates and velocities for the next time step using
the above described equations of motion, a time integration algorithm is required.
The GROMACS MD program utilizes the so-called leap-frog algorithm which uses
coordinates ri at time t and velocities vi at time t − ∆t2 in order to update the
positions and velocities using the forces F(t) at time t. The equations of the leap-frog
algorithm for particle i are written as follows:
vi(t+
∆t
2
) = vi(t− ∆t
2
) +
Fi(t)
m
∆t; (3.8)
ri(t+ ∆t) = ri(t) + vi(t+
∆t
2
)∆t. (3.9)
The algorithm is of third order in r, time-reversible and equivalent to the Verlet
algorithm [100]. See reference [101] for further details and comparison with other
time integration algorithms.
3.6 Periodic boundary conditions
Several ways to treat the boundaries - and therefore to minimize the edge effects
caused by a small isolated system - of the simulated system exist. The classical
way is to use periodic boundary conditions (PBCs) where the atoms of the system
to be simulated are put into a space-filling box surrouded by translated copies of
itself thus forming an infinite lattice [102]. Therefore, as the particle moves in the
original box, its periodic image in each of the neighbouring boxes moves in exactly
the same way. Due to this, if the particle crosses one side of the simulation box, it
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immediately re-enters from the opposite side. Since the particles interact with its
nearest neighbours, it does not matter whether the neighbour is in the original box
or in one of its copies because the interactions are calculated over the box boundaries.
Attention should be paid to the size of the box since if it is defined to be too small,
the atoms residing near the box boundaries will experience the interactions caused
by the other atoms more than once and from several directions causing the unwanted
edge effects. When the PBCs are applied in the simulations concerning CETP and
anacetrapib, the quadratic simulation box containing the protein and the drug is
copied on every side of the original box and the same is done for these new boxes.
Hence the system can be considered as infinite with an infinite number of proteins
and drugs surrounded by water.
3.7 Temperature and pressure coupling
Maintaining the constant temperature through a simulation can be achieved for
instance through the Berendsen or the Nose´-Hoover coupling [103, 104]. In the
Berendsen coupling, the system is weakly connected to an external heat bath given
temperature T0. The temperature difference decays exponentially with a time constant
τ :
dT
dt
=
T0 − T
τ
(3.10)
The advantages of this coupling method are that the strength of the coupling can
be varied to adapt the user requirement as well as that the algorithm is extremely
efficient to equilibrate the system to the target temperature [103]. However, the
Berendsen coupling method suppresses the fluctuations of kinetic energy meaning
that a proper canonical ensemble cannot be generated. This can be achieved through
the Nose´-Hoover coupling applied in this study. The Nose´-Hoover method introduces
a thermal reservoir and a friction term in the equations of motion:
d2ri
dt2
=
Fi
mi
− ξ dri
dt
, (3.11)
where ξ is the dynamic friction parameter connected to the deviation from the desired
temperature. The equation of motion for this parameter is defined as
dξ
dt
=
1
Q
(T − T0). (3.12)
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The strength of the coupling is determined by the parameter Q and the reference
temperature T0.
In the same spirit also the pressure coupling of the system can be described.
Pressure coupling can be achieved either through the Berendsen algorithm which
scales the coordinates and box vectors at every time step or through the Parrinello-
Rahman approach representing the equations of motion also for the box vectors [105].
Therefore the Parrinello-Rahman pressure coupling is similar with the Nose´-Hoover
scheme. The Berendsen pressure coupling relaxes the pressure in the following way:
dP
dt
=
P0 −P
τp
(3.13)
with a scaling matrix µ given by
µij = δij − ∆t
3τp
βij{P0ij − Pij(t)}. (3.14)
Here δij is the Kronecker delta being one when i and j are equal and zero otherwise,
βij is the isothermal compressibility of the system, τp being the time constant for
pressure coupling and P0ij being the target pressure. In cases where it is important to
calculate the thermodynamical properties accurately, the Parrinello-Rahman pressure
coupling is used. This approach is applied in this study. In the Parrinello-Rahman
algorithm, the box vectors represented by the matrix b obey the following equation
of motion:
db2
dt2
=
V
Wb
(P−Pref ) (3.15)
where V is the volume of the box, W is a parameter which determines the strength
of the coupling and P and Pref represent the current and reference pressures,
respectively.
3.8 Long-range interactions
In MD simulations it is important to treat the long-range interactions accurately.
Long-range interactions are potentials that decay slowly, such as the electrostatic
potentials. Ewald summation is a technique to efficiently sum the long-range in-
teractions between particles and all their infinite periodic images [106]. However,
this method is not suitable for large systems since the computational cost of the
reciprocal term of the sum increases too much. Therefore the Particle-mesh Ewald
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(PME) method was developed to improve the calculation of the reciprocal sum and
in this way to increase the computational efficiency [106].
3.8.1 Ewald summation
The total electrostatic energy of N particles and the periodic images are given by
V =
f
2
∑
nx
∑
ny
∑
nz
N∑
i
N∑
j
qiqj
rij,n
, (3.16)
where nx, ny and nz are the box vectors and rij,n is the real distance between
the charges and not the minimun-image. The sum is very slow but conditionally
convergent. In order to increase the computational efficiency, the Ewald summation
method was introduced. In this method the idea is to convert the single slowly-
converging sum presented in equation 3.16 into two quickly-converging terms and a
constant term as follows:
V = Vdir + Vrec + V0 (3.17)
where Vdir represents the direct (real) sum, Vrec is the reciprocal (imaginary, or
Fourier) sum and V0 is the constant term. These terms are written as
Vdir =
f
2
N∑
i,j
∑
nx
∑
ny
∑
nz
qiqj
erfc(βrij,n)
rij,n
, (3.18)
Vrec =
f
2piV
N∑
i,j
qiqj
∑
mx
∑
my
∑
mz
exp(−(pim
β
)2 + 2piim(ri − rj))
m2
, (3.19)
V0 =− fβ√
pi
N∑
i
q2i . (3.20)
Here β determines the relative weight of the direct and reciprocal sums, V is the
volume of the simulation box, m is a reciprocal-space vector and erfc is the error
function that decreases monotonically as t increases. It is written as follows [106]:
erfc =
2√
pi
∫ ∞
x
exp(−t2)dt (3.21)
With these equations it is possible to use a short cutoff in both the direct and
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reciprocal space sum. However, it is not realistic to use this for large systems since
the computational cost of the reciprocal term increases as N2.
3.8.2 Particle mesh Ewald-method
PME is a method developed to improve the performance of the reciprocal sum by
splitting the total electrostatic energy into local interactions. The idea is to put
a fine mesh on top of the system and then distribute the charges onto the mesh
points [107]. The electrostatic potential is calculated by solving the Poisson equation
on the mesh using the fast Fourier transformation for the reciprocal sum allowing an
efficient calculation [106]. The forces on each atom are then calculated by numerically
differentiating the potential and interpolating back from the mesh to the position
of the atom, thus reducing memory requirements [107]. The charge interpolation
function originally used was Lagrange interpolation but an enhanced PME uses the
B-spline interpolation function due to the fact that it is smoother and allows higher
accuracy by increasing the order of interpolation. See reference [106] for further
details.
The direct sum is evaluated explicitly using cutoffs [106]. When computing the
direct sum, the relative weight factor β presented in equation 3.18 is chosen large
enough in order to apply a fixed cutoff radius [106]. This reduces the complexity
of the direct sum. PME has several advantages in addition to the improvement
in the computational cost. It is more accurate than the Ewald summation and,
moreover, the accuracy can be improved by adjusting a few parameters [106]. Other
ways to treat the long-range interactions include the reaction field method and the
particle-particle particle-mesh method but these are not discussed further since the
PME method is the one applied in this study.
3.9 Constraints
In classical MD simulations the time step is limited by bond oscillations having a
relatively high frequency and low amplitude [108]. In order to increase the time
step in simulations, the bonds and bond angles can be treated as constraints on
the equations of motion. Constraints are algorithms implemented after the force
calculations to freeze the unwanted highest frequency vibrations since the movements
of covalent bonds in the system can be adjusted using constraints [98]. In other
words, constraints force the bonds to stay at the proper length or angle. In addition,
a constrained bond resembles more closely a quantum oscillator in its ground state
than a classical oscillator, making it physically a more realistic model for a covalent
bond. Examples of constraint algorithms include LINCS, SHAKE, SETTLE and
RATTLE.
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LINCS is a constraint algorithm that resets bonds to their correct lengths after
an unconstrained update [108]. This method is non-iterative since it always uses two
steps and it can therefore be easily parallelized, thus improving the computational
efficiency. In addition, LINCS is more stable and faster in comparison with SHAKE
but the disadvantage of this method is that it can only be used with bond constraints
and isolated angle constraints. SHAKE-algorithm was introduced on the basis of
the leap-frog Verlet scheme. It changes a set of unconstrained coordinates r′ to a
set of coordinates r′′ which fulfill the list of distance constraints using a set r as
a reference [98]. Therefore it is an iterative method and the most widely used for
large molecules. Compared with SHAKE, SETTLE operates in a similar manner
but solves the problem analytically [108]. It avoids the linearization of the equations
but requires the evaluation of ten square-root functions per tri-atomic molecule [109].
Due to this, the SETTLE algorithm is too complicated for large molecules but faster
for small molecules when compared with SHAKE. RATTLE is a velocity version
of the SHAKE algorithm. In addition to the calculation of the positions of the
particles, RATTLE calculates the velocities at the next time step from the velocities
at the present time step [110]. At each time step the algorithm guarantees that
the coordinates and velocities of the atoms satisfy the internal constraints. When
compared with SHAKE, RATTLE is more accurate and easier to modify for the
use of MD methods with constant temperature and constant pressure since it deals
directly with velocities.
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4. SIMULATION MODELS AND ANALYSIS
METHODS
This chapter consists of two sections. The first section describes the force fields used
for different molecule types, the initial structures of the simulated systems in detail
as well as the simulation parameters used. The second section lists and describes all
the methods applied to analyze the obtained data from MD simulations.
4.1 Simulation systems and details
The MD simulations performed in this study serve as pioneer simulations in the field
of research concerning the interactions between CETP and the novel molecular agent
anacetrapib. The results of these simulations can be utilized when studying the
corresponding interactions between CETP and the former developed agent torcetrapib
and furthermore, when new potential molecular agents are developed. The computing
facilities needed in this study were offered by the Finnish IT Centre for Scientific
Computing. The simulations and their analysis were performed with the GROMACS
software package, version 4.5.4 [97]. GROMACS is a widely applied simulation
package for MD simulations including a large set of ready-made analysis tools.
4.1.1 Force fields and initial configurations
The coordinate file for CETP was acquired from the Protein Databank with an
accession code 2OBD [57]. In addition to CETP, this file provides information of the
atomic positions of the lipids involved in CETP, namely the two CEs located inside
the hydrophobic tunnel and the two DOPC lipids that block the openings of the
tunnel. The coordinate file of anacetrapib was obtained from Artturi Koivuniemi.
The force fields for these lipids as well as for anacetrapib were obtained from To´masz
Rog whereas the force field used for CETP was the official distribution force field
denoted as optimized potential for liquid simulations all-atom (OPLS-AA) [111]. The
all-atom force field, as the name implies, is an explicit representation of all atoms
in the simulated system, including the nonpolar hydrogens. Water molecules were
described with the TIP3P model since it is compatible with the parametrization of
OPLS-AA.
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The starting structures of the simulations were determined and validated with the
help of molecular docking calculations. The purpose was to explore the most probable
sites from the crystal structure of CETP where anacetrapib desires to attach. In
addition, also the optimal docking conformations of the drug can be obtained from
the calculations. The program applied for these purposes was AutoDock Vina. Its
technical details can be found in [112]. The program is able to select the protein-
ligand complexes in terms of the lowest binding energy without prior knowledge of
the binding site. In order to reduce the impact of protein flexibility, the structure of
CETP was held rigid. The obtained results are presented in Figure 4.1 with ligands
colored with red, brown, cyan and green representing the most probable binding
sites and conformations of anacetrapib. The binding energies of these sites are
-11.4 kcal mol−1, -11.1 kcal mol−1, -11.6 kcal mol−1 and -11.2 kcal mol−1, respectively.
The binding site of the ligand colored with brown is positioned in the hydrophobic
pocket in the N-terminal domain and is mainly formed by the residues Thr23, Ile27,
Ala30, Ile82, Ala191, Val194, Gln195, Arg197, Ala198 and Leu463. Some of these
residues surround the binding site of the red ligand located at the N-terminal tunnel
opening. Other important residues for this domain are Phe467-Leu471. The binding
site of the green ligand is also located in the hydrophobic pocket but in the C-terminal
domain. The surrounding residues are Ala273, Leu283, Val342, Phe344, Tyr371,
Lysh373, Leu421, Phe425, Asp448 and Asp456. The cyan ligand is located on a
region between the above mentioned residues. Dong et al. [113] have obtained similar
results with N,N -disubstituted -trifluoro-3-amino-2-propanols-based inhibitors of
CETP.
Figure 4.1: The binding sites and conformations of anacetrapib within the structure
of CETP obtained from the molecular docking calculations. The binding
energies for the binding sites of red, brown, cyan and green ligands are
-11.4 kcal mol−1, -11.1 kcal mol−1, -11.6 kcal mol−1 and -11.2 kcal mol−1,
respectively.
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The initial structures of the simulations were determined based on the results
obtained from the molecular docking calculations presented in Figure 4.1 and they
can be divided into two groups. The first group consists of four systems where
anacetrapib was placed in the lipid binding pocket, whereas the second group consists
of six systems including the drug placed outside of CETP but in the vicinity of the
lipid binding pocket. Depending on the system, the lipid binding pocket included
CEs and in addition, the openings of the tunnel were either unblocked or blocked by
DOPCs. The two groups differ from each other also when concerning the simulation
time. The group in which anacetrapib interacted with CETP from the lipid binding
pocket was simulated for 200 ns, whereas the group with interactions occurring
between the drug and the concave surface of CETP was simulated for 20 ns.
Building the initial configuration of each system required a manual placing of
the molecules in order to achieve the wanted starting structure. This was done by
using the visual molecular dynamics (VMD) program often used for displaying and
animating biomolecular systems [114]. The construction was started from the group
of longer simulated systems. The first system (L1-200ns) consists of CETP and two
DOPC lipids that block the openings of the empty lipid binding pocket. The starting
structure for this system was obtained directly from the Protein Databank with
the removal of CEs. The starting configuration for the second system (L2-200ns) is
presented in Figure 4.2. This system includes CETP, two DOPCs (red space fills)
to block the openings of the tunnel as well as two anacetrapibs (cyan-white space
fills) placed in the vicinity of cysteine amino acids (blue space fills) of CETP. The
sites of the drug molecules correspond to the binding sites of cyan and green ligands
presented in Figure 4.1. Anacetrapibs were placed in the lipid binding pocket in a
way that their oxygen groups were oriented towards the cysteines since it is expected
that these functional groups will form hydrogen bonds with cysteines residues thus
stabilizing the CETP-anacetrapib complex. The starting configuration of the third
200 ns simulation (L3-200ns) differs from the previous one in a way that two CEs are
placed in the hydrophobic tunnel of CETP instead of anacetrapibs. This structure
is presented in Figure 2.5. In the fourth system (L4-200ns) DOPCs and CEs were
removed from the structure and one anacetrapib was placed in the lipid binding
pocket between the binding sites determined by the cyan and green ligands. Each
system was solvated with approximately 108000 water molecules and neutralized with
15 sodium atoms since CETP has a net charge of -15e. The reason for neutralizing
the systems is that life does not exist at net charge. In addition, the PME method
described in Section 3.8 would produce artifacts if the total charge of the system
differs from zero. Therefore the systems consisted of a total of 332076, 332175, 332414
and 331794 atoms, respectively.
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Figure 4.2: The starting structure of the second 200 ns simulation. The system includes
CETP, two DOPC lipids to cover the openings of the tunnel and two anace-
trapibs placed in the vicinity of cysteine amino acids. DOPCs are drawn as
red space fills, anacetrapibs as cyan-white space fills and cysteine residues as
blue space fills. For the sake of clarity, water is not shown.
After building the initial configurations for the longer simulations, the construction
was started for the group of shorter simulations. In these simulations one anace-
trapib molecule was placed outside of empty CETP. In the first simulation (S1-helix)
anacetrapib was placed 1 nm distance from helix X. Concerning the four following
systems (S2-1nm, S3-2nm, S4-3nm and S5-4nm), anacetrapib was placed 1, 2, 3 and
4 nm distance from the two tunnel openings, respectively. In Figure 4.3 is presented
the starting configuration for the simulation S3-2nm. The sixth system (S6-convex)
differs from the previous ones since anacetrapib was placed 3 nm distance from the
convex back of the protein. After the systems were built, they were solvated with
approximately 108000-163000 water molecules depending on the size of the simula-
tion box. The simulation boxes in simulations S4-3nm, S5-4nm and S6-convex were
larger since the distance between the particles was larger compared with simulations
S1-helix, S2-1nm and S3-2nm. Hence a larger number of water molecules was needed
to fill the box. The systems were neutralized in a similar manner than in the longer
simulations, and thus the systems consisted of a total of 331725, 331743, 331743,
497097, 497085 and 497151 atoms, respectively. After the systems were constructed,
solvated and neutralized but before any simulation was started, energy minimization
was performed for each system using the steepest descent method and 500 steps. All
the simulations, their abbreviations and simulation times are listed in table 4.1.
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Figure 4.3: The starting structure of the third 20 ns simulation. The system includes
CETP and anacetrapib placed 2 nm distance from the tunnel openings.
Anacetrapib is drawn as cyan-white space fills. For the sake of clarity, water
is not shown.
Concerning the simulations performed for 200 ns, the first and the third simulation
(L1-200ns and L3-200ns) without anacetrapibs serve as the control simulations for
the other two 200 ns simulations. The purpose of control simulations is to help the
analysis of the results including anacetrapib (L2-200ns and L4-200ns), since with their
help, it is possible to more easily distinguish the changes in the secondary structure
of CETP induced by the drug. The shorter 20 ns simulations were constructed to
reflect ’random’ initial conditions where anacetrapib appears in a randomly chosen
location around CETP. The reason to perform several simulations of this kind was
to see the diffusion process, that is, the process of self-assembly of how anacetrapib
forms a complex with CETP and whether there is a long-range force that drives the
drug in the vicinity of CETP. With the help of these simulations it is also possible
to evaluate the consistency of the obtained results in a manner that whether or not
they end up in similar locations and final conformations defined by the red ligand in
Figure 4.1. In addition, the purpose was also to evaluate the interactions between
anacetrapib and the concave surface of CETP and to see the effects of anacetrapib
on the conformation of helix X.
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Table 4.1: The performed MD simulations, their abbreviations and simulation times.
Abbreviation System Time
L1-200ns CETP, 2 x DOPC 200 ns
L2-200ns CETP, 2 x DOPC, 2 x anacetrapib 200 ns
L3-200ns CETP, 2 x DOPC, 2 x CE 200 ns
L4-200ns CETP, anacetrapib 200 ns
S1-helix CETP, anacetrapib 1 nm from helix X 20 ns
S2-1nm CETP, anacetrapib 1 nm from tunnel openings 20 ns
S3-2nm CETP, anacetrapib 2 nm from tunnel openings 20 ns
S4-3nm CETP, anacetrapib 3 nm from tunnel openings 20 ns
S5-4nm CETP, anacetrapib 4 nm from tunnel openings 20 ns
S6-convex CETP, anacetrapib 3 nm from the convex back 20 ns
4.1.2 Simulation parameters
The actual simulations were performed under NpT conditions (constant number of
particles, pressure and temperature). The reference temperature for all simulated
systems was 310 K and each component of the system was separately coupled to
the temperature bath using the Nose´-Hoover coupling method with time constant of
0.1 ps. The used pressure coupling method was Parrinello-Rahman barostat with
isotropic pressure coupling and a coupling constant of 1 ps and the reference pressure
of 1 bar. The time step of 2 fs was used for time integration and all bonds were
constrained using the LINCS algorithm. The van der Waals interactions were chosen
to have a cutoff at 1 nm. The long-range electrostatic interactions were evaluated by
the PME method with a 1 nm cutoff for the Coulombic interactions. After completion
of each simulation the respective trajectory files were analyzed with different tools of
GROMACS.
4.2 Analysis methods
The structure, properties and interactions of CETP and anacetrapib can be analyzed
using various methods. The observables found in MD simulations, the velocities and
positions of the particles for example, can be used to express physical quantities
that can be compared with experimental data, if available. This section covers the
methods used to analyze the simulations and is based mostly on the manual of
GROMACS [97]. All the applied analysis tools are ready-made and distributed with
GROMACS.
4. Simulation models and analysis methods 45
4.2.1 Analysis of secondary structure elements
The secondary structure elements of a protein can be calculated with a define
secondary structure of proteins (DSSP) program. The purpose of this analysis is
to measure the most likely secondary structure of the protein as a function of time.
This is achieved by reading the positions of the atoms followed by a calculation of
hydrogen bond-energies between all atoms [115]. The best two hydrogen bonds for
each atom are then used in order to determine the most likely class of secondary
structure for each residue [115]. In other words, the DSSP program breaks down
the different secondary structure elements (i.e. helix, sheet, turn, bend, etc.) of
individual residues for each time step and allows the visualization of the data [116].
From this plot it is easy to see the stability (or de-stability) of secondary structure
elements as a function of time.
The algorithm for extracting the different structural elements from the atomic
coordinates is a process of pattern-recognition mainly based on hydrogen bonding
patterns. This is due to the fact that the presence or absence of a hydrogen bond can
be characterized by a single decision parameter, namely a cutoff in the bond energy.
The electrostatic interaction energy between two hydrogen bonding groups can be
calculated by placing partial charges on the C,O (+q1,−q1) and N,H (−q2,+q2)
atoms written as follows [117]:
E = q1q2
(
1
rON
+
1
rCH
− 1
rOH
− 1
rCN
)
f (4.1)
where q1=0.42e and q2=0.20e, e being the unit electron charge and rAB the interatomic
distance between atoms A and B. f in a dimensional factor with a value of 332. The
unit binding of energy E is expressed as kcal mol−1. A good hydrogen bond has a
binding energy of about -3 kcal mol−1 [117].
The patterns of hydrogen bonding define a hierarchy: n-turns with a hydrogen
bond between the CO-group of residue i and the NH-group of residue i+ n, where
n = 3, 4, 5 and bridges with a hydrogen bond between residues that are not near
each other in sequence [117]. These two types of patterns essentially cover all the
backbone-backbone hydrogen bonds. α-helices and β-sheets are defined by repeating
4-turns and bridges, respectively. The different secondary structure elements are
discussed in more detail in Section 3.2.
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4.2.2 Root mean square deviation
The root mean square deviation (RMSD) is used to evaluate the deviation of the
structure of the simulated system from the initial starting structure over the course of
simulation. RMSD can be calculated by least-square fitting the simulated structure
to the reference structure (t2 = 0):
RMSD(t1, t2) =
√√√√ 1
M
N∑
i=1
||miri(t1)− ri(t2)||2 (4.2)
where M is the sum of particle masses and ri(t) is the position of atom i at time t.
The smaller the obtained RMSD value, the smaller the deviation between the final
and initial structures and moreover, the more similar the structures are. In order to
determine the structural similarity, an arbitrary RMSD cutoff has been chosen to
indicate that changes on the order of 0.1-0.3 nm are acceptable and expected [118].
4.2.3 Radius of gyration
Radius of gyration is used to measure the compactness of the structure of the protein
as a function of time. It is mathematically defined as the mean square distance
of each particle in the structure with respect to its center of mass rcm. Hence it
describes how the mass is divided around rcm. The equation is written as
Rg =
√〈∑
imi(ri − rcm)2∑
imi
〉
, (4.3)
where the center of mass is defined as
rcm =
∑N
j=1mjrj∑N
j=1mj
. (4.4)
In this study the radius of gyration is calculated for CETP in order to measure
the changes in the structure of the protein as a function of time.
4.2.4 Root mean square fluctuation
The root mean square fluctuations (RMSF) of atomic positions are used to discover
and evaluate the most flexible regions of CETP. RMSFs can be calculated by fitting
the simulated structure to a reference structure. The RMSF profile reveals the residues
4. Simulation models and analysis methods 47
of CETP that fluctuate the most during the simulation. Therefore, the higher the
obtained RMSF value, the more the residues in question fluctuate. Typically, the
most fluctuating residues of a protein can be found in loop-regions. RMSF values
can also be converted into B-factor values which can then be visualized.
4.2.5 Principal component analysis
Principal component analysis (PCA), also known as the covariance analysis, is used
to find correlated motions. During a simulation, both collective motions and local
fluctuations occur simultaneously which complicates the distinction between the two
types of motion from each other [119]. PCA helps in such cases since it can filter the
global, collective (slow) motions from the local (fast) motions. It uses the covariance
matrix C of the atomic coordinates:
Cij =
〈
M
1
2
ii (xi − 〈xi〉)M
1
2
jj(xj − 〈xj〉)
〉
(4.5)
where M is a diagonal matrix containing the atom masses (mass-weighted analysis)
or the unit matrix (non-mass weighted analysis) and xi is the position of atom i.
C is a symmetric 3N∗3N matrix which can be diagonalized with an orthonormal
transformation matrix R defining a transformation to a new coordinate system:
RTCR = diag(λ1, λ2, ..., λ3N) (4.6)
where the eigenvalue λ1 ≥ λ2 ≥ ... ≥ λ3N . Diagonalization produces a set of
eigenvectors (columns of R) and eigenvalues that describe the collective modes of
fluctuations [119], where the eigenvectors represent the direction of motion and the
eigenvalues represent the amount of motion along the eigenvectors [120]. Those
eigenvectors that correspond to the largest eigenvalues are denoted as principal
components since they represent the collective motions with largest amplitude. After
diagonalization the trajectory can be projected on the eigenvectors in order to give
the principal components pi(t) presented as follows:
p(t) = RTM
1
2 (x(t)− 〈x〉). (4.7)
The eigenvalue λi is the mean square fluctuation of principal component i. The
first few principal components describe the collective, slow motions in the system.
The trajectory can be filtered along one or more principal components. For one
principal mode this is written as:
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xf (t) = 〈x〉+M− 12R∗ipi(t). (4.8)
When this analysis is performed on a macromolecule, usually the overall rotation
and translation are removed in order to look at the internal motion only. This can
be achieved by least square fitting to a reference structure.
4.2.6 Hydrogen bonds
Hydrogen bond formation has a remarkable role, e.g., in the stabilization of the
secondary structure of a molecule. In this study the formation of hydrogen bonds
is analyzed between CETP and anacetrapib in order to see where and how tightly
anacetrapib binds. The formation of hydrogen bonds during a simulation can be
analyzed between all possible donors D and acceptors A. OH and NH groups are
regarded as donors and O is always an acceptor [121]. The determination if a
hydrogen bond exists, is done by using a geometrical criterion based on the distance
between hydrogen-acceptor rHB and the angle between acceptor-donor-hydrogen
triplet αHB:
r ≤ rHB = 0.35nm, (4.9)
α ≤ αHB = 30◦ (4.10)
There are several ways to calculate the hydrogen bonds between two groups of
atoms including the calculation of donor-acceptor distance distribution of all hydrogen
bonds and the hydrogen-donor-acceptor angle α distribution of all hydrogen bonds,
but the one applied in this study is the calculation of the total number of hydrogen
bonds in each time frame.
4.2.7 Interaction energies
Concerning the MD simulations performed for 20 ns, it is important to calculate
the interaction energies in order to determine the type of non-bonded interaction
that drives the diffusion process between CETP and anacetrapib. The non-bonded
interactions contain a repulsion term, a dispersion term and a Coulomb term. The
repulsion and dispersion terms are combined and described in terms of the weak
van der Waals interactions. The Coulombic potential describes the electrostatic
interactions. Van der Waals interaction energy can be calculated using the LJ
potential presented in equation 3.4 and the electrostatic interaction energy using the
Coulombic potential presented in equation 3.5.
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4.2.8 Spatial density map
A spatial density map determines the 3D structure around a chosen molecule. It is
determined based on the spatial distribution function (SDF) which indicates how
much the prespecified residues move related to the rest of the molecule during the
simulation. The SDF consists of two terms, namely, the radial distribution function
and the radial angular distribution function. It can be written as
g(r) ≡ g(rij) = 〈g(rij, ωj)〉ωj . (4.11)
Hence it is a function of the positions r and orientations ω of all the molecules in
the system. 〈...〉ωj denotes the average over all orientations of the molecule j [122].
g(rij) represents the radial distribution function which is presented as
g(rij) =
〈δ(|rij| − r)〉
4piρr2
∆r, (4.12)
where ρ is the density of the molecules [123]. The term g(ω) in equation 4.11 is the
radial angular distribution function written as
G(r, θ) =
1
Nρ(r, θ)
〈
∑
i
∑
j 6=i
δ(r − rij)δ(θ − θij)〉, (4.13)
where ρ(r, θ) is the number of molecules in the volume element presented as [123]
ρ(r, θ) =
(
N
V
)
2pir2 sin θ∆r∆θ. (4.14)
In order to properly calculate a meaningful SDF, the particle of interest must be
centered within the simulation box over the course of the simulated trajectory, and
rotational and translational motions must be removed. This implies that the SDF
for the surrounding species must be assembled based on a relatively fixed reference.
The result obtained from the analysis can then be visualized. In this study, the SDF
is determined for DOPC, CE and anacetrapib molecules in order to see how they
move in the lipid binding pocket of CETP.
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5. RESULTS AND DISCUSSION
In this work, the interactions between CETP and anacetrapib were studied. A
total of ten MD simulations were performed with different starting structures and
simulation times. Four of the systems were simulated for 200 ns whereas six of them
for 20 ns. This chapter presents the most important findings obtained from the
simulations. All snapshots of simulated systems are produced using VMD and the
graphs are plotted using MATLAB R©.
5.1 200 ns simulations
The purpose was to study the conformational changes of CETP induced by anace-
trapib through the investigation of which regions of the protein were involved in
the stability and which were related to structural fluctuations. In addition, regions
with the biggest structural changes and their causes were examined. The changes in
helix X and DOPCs were of great importance because of their crucial roles in the
process of neutral lipid exchange. The simulations without anacetrapib (L1-200ns
and L3-200ns) served as control simulations for the other two since the comparison
between these two groups enable a more elaborate specification of the structural
changes induced by the drug.
5.1.1 Generic stability
An initially random system requires time to reach a stable free energy minimum. The
equilibration process of the system is affected by every external change and hence
the state of equilibrium has to be observed. In this work, equilibrium is defined as a
state where the large-scale motions are absent. In addition, the individual molecules
are free to move around but no longer tend to move in any specific direction. The
equilibration process is studied through the RMSD values plotted as a function of
time in Figure 5.1. Before performing the analysis, water molecules were removed
from the system in order to simplify the calculations. The graph presents the total
RMSDs as well as the values for DOPCs, CEs and anacetrapibs. The profiles indicate
that the structures do not deviate considerably from the X-ray structure. This is
supported by data for the radii of gyration that fluctuated between 3.3 and 3.45 nm,
see Figure 5.2.
5. Results and discussion 51
(a) L1-200ns
(b) L2-200ns
(c) L3-200ns
(d) L4-200ns
Figure 5.1: RMSD profiles of whole systems (blue) listed in table 4.1, DOPC (red), CE
(green) and anacetrapib (black) molecules for the MD simulations performed
for 200 ns.
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Figure 5.2: Radius of gyration profiles of MD simulations performed for 200 ns.
5.1.2 Role of phospholipids in the neutral lipid exchange
Despite the stable average structures of systems during the simulations, local fluc-
tuations as well as structural changes occur. These alterations can be analyzed on
different levels by examining individual molecules or larger molecular groups. The
biggest interest is directed to DOPCs, helix X and to the changes occurring in them
since these structures regulate the process of neutral lipid exchange. In addition, the
influence of anacetrapib in these conformational fluctuations is of great importance
due to its role in the inhibition of CETP.
The regulatory role of helix X in the lipid exchange process has been found to be
significant regarding the functions of CETP [55, 59, 60]. Another crucial component
in this process is PLs due to their central role both in the binding and detachment of
CETP from lipoprotein surfaces. During binding, PLs have been proposed to merge
into the monolayer followed by a migration away from the tunnel openings [55, 59].
This induces a formation of a hydrophobic pathway under the concave surface of the
protein which permits the access of lipids into the tunnel. Concerning the detachment,
the tunnel openings will need to be refilled with PLs before the dissociation since
otherwise the protein would not be able to return to aqueous environment [55]. Wide
attention has been paid to the mechanisms of anacetrapib affecting the regulation of
these structural regions of CETP since they are regarded as essential parts of the
protein’s ability to change the lipids. As a consequence, the drug has been speculated
to lock helix X in the open state [59, 70]. This could hinder the dissociation of the
protein as well as the binding of PLs to the C-terminal opening further inhibiting
CETP. However, the precise inhibitory mechanism is still unclear and thus further
investigations are needed. Despite this, PLs have an evident role in the exchange
and transportation of neutral lipids. This issue will be discussed in detail next.
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The RMSD profiles of DOPCs presented in Figure 5.1 imply increased confor-
mational changes of DOPCs when anacetrapib is transferred into the hydrophobic
tunnel. As can be seen, the RMSD fluctuates between 0.33 and 0.48 nm without the
drug and between 0.4 and 0.65 nm with the drug. This result is further supported by
the atomic RMSFs of DOPCs presented in Figure 5.3 as well as the corresponding
spatial density maps colored with gray. The observed high fluctuations suggest that
anacetrapib interacts with PLs and consequently this would destabilize the binding
of DOPCs to CETP. Moreover, destabilization could reduce the ability of PLs to
refill the tunnel openings stabilizing the CETP-lipoprotein complex.
Interestingly, the high fluctuations of DOPCs were observed also without anace-
trapibs but when two CE molecules filled the length of the tunnel, see Figure 5.3 d.
The spatial density map reveals the trajectory of DOPCs to be as wide-ranging as
the one containing two anacetrapib molecules. The movement could be caused by the
residence of lipids inside the hydrophobic tunnel, since in order for these molecules
to properly accomodate the cavity, a conformational rearrangement of DOPCs would
be required. As a consequence, some regions in the structure of PLs succumb. Either
way, the movement of PLs indicates the structure of CETP to be rather unstable
during the transportation of neutral lipids. This could highlight the role of helix X
needed to prevent the structure of the protein from collapsing. In addition, helix X
may be needed to interact with CEs in order to make their exchange possible. This
is supported by several mutational studies claiming that CETP can transfer PLs but
not neutral lipids without helix X [68, 69]. We will return to this issue later.
5.1.3 Mobility of helix X
RMSFs of the protein backbone were analyzed in order to find the regions that
fluctuated the most during the simulations. This method of analysis can give
extremely valuable information by highlighting the regions of protein backbone with
low and high mobility. In addition, it provides structural information by detecting
different elements of the protein secondary structure. Figure 5.4 shows the RMSFs of
each simulation as a function of the residue number as well as the residual B-factors
mapped to the backbone structure of CETP. As can be noticed, similar results were
observed in all simulations.
CETP has previously been reported to have mobile structures with elevated B-
factors near tunnel openings including the hinge region of helix X and in the N- and
C-terminal ends including the loop regions represented with omegas Ω1 and Ω2 [55].
As expected, these regions showed the highest mobility, with the conformational
fluctuation of helix X peaking near the residue 462. In addition, five other regions in
the backbone of the protein were found to fluctuate highly during each simulation.
These regions were Ω3 (residues 380-400), Ω4 (residues 40-50), Ω5 (residues 90-110)
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(a)
(b) L1-200ns, DOPCs (c) L2-200ns, DOPCs
(d) L3-200ns, DOPCs (e) L3-200ns, CEs
(f) L2-200ns, anacetrapibs (g) L4-200ns, anacetrapib
Figure 5.3: a) RMSF profiles of MD simulations performed for 200 ns. Atoms 7441-7716
correspond to DOPCs (L1-200ns, L2-200ns and L3-200ns). The peaks indicate
the atoms that fluctuated the most during the simulations. b) - g) Spatial
density maps for DOPCs, CEs and anacetrapibs. The map is colored with
gray revealing the movement of the molecules inside the lipid binding pocket
of CETP.
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(a)
Ω1
Ω2
Ω3
Ω4
Ω5
Ω6
Helix X
(b)
Figure 5.4: a) Residual RMS fluctuations of MD simulations performed for 200 ns. The
peaks indicate the regions of CETP that fluctuated the most during the
simulations. These regions are found in the loops marked with omegas as well
as in the residues corresponding to helix X. b) Residual B-factors mapped to
the backbone structure of CETP. Red color indicates the most rigid regions
in the structure whereas white and blue indicate the most flexible structural
regions. Loop regions are marked with omegas and the region corresponding
to helix X is labeled.
and Ω6 (residues 150-170) which were earlier shown to have high mobility [59]. All
these regions are found in the loops and therefore the high fluctuations can be
expected. The observed results were confirmed by the results obtained from PCA
which showed the movement of the biggest amplitude to reside in the loops (data
not shown). The results imply that the structure of CETP is elastic which could
facilitate the binding to lipoprotein surfaces with varying curvatures. In addition,
the observed flexibility of the hinge region could assist the lipid exchange process.
Similar results were observed in [59].
5.1.4 Structure fluctuations of helix X
As mentioned, the regulatory role of helix X has been identified to play an important
role in the lipid exchange process. The structure of helix X has been proposed to
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undergo conformational changes during lipoprotein binding by moving aside from
the N-terminal tunnel opening or by rearranging and becoming buried inside the
hydrophobic pocket [59, 60]. These changes could assist the transfer of lipids between
CETP and lipoprotein particles. In addition, helix X is needed to shield the tunnel
opening before detachment to make CETP more compatible with the surrounding
aqueous environment [55]. These observations suggest that helix X acts as a lid
conducting the lipid exchange by alternating its open and closed states.
The conformational changes of helix X can be studied through the DSSP analysis
which is a standard method for assigning the changes in the secondary structure to
the different residues of the protein. Concerning the performed MD simulations, it
became apparent that the secondary structure of helix X experienced considerable
fluctuations between turn (unfolding of the helix) and 310-helix (the extension of the
helix) when either CEs or anacetrapibs were present in the hydrophobic tunnel, see
appendix A.1. This proposes that the drug induces conformational fluctuations to
the helix which could indicate substantial effects on the lipid transfer functions of
CETP.
On the basis of the above findings, the conformational rearrangement of helix
X can be speculated to affect the lipid exchange in two different ways. First, the
changes induced by the drug could enforce the helix to favor the open state. This
would hinder the detachment of CETP from lipoprotein surfaces stabilizing the
complex. In addition, it is probable that the open state may prevent CETP from
binding and transporting PLs. Second, it is possible that the rearrangement locks
the helix in the closed state reducing the ability of the protein to bind HDL. This
suggestion is supported by the visualization of the simulation trajectory that revealed
the reluctance of the helix to move aside from the tunnel opening. However, these
simulations were carried out without a lipoprotein particle and hence the above
discussion is only suggestive. Therefore additional simulations including the complete
lipoprotein-CETP-anacetrapib complex are needed to confirm these issues.
Previous suggestions have expressed that the movement of helix X aside from the
N-terminal tunnel opening is sufficient for the lipid exchange to occur [60]. However,
this is in contradiction to several mutational studies that showed CETP to be capable
of transfering PLs but not TGs or CEs when helix X was completely removed from
the structure [68, 69]. Due to this, the role of helix X may not be as simple as
previously suggested. Since helix X experienced conformational fluctuations when
CEs accomodated the hydrophobic tunnel, helix X can be suggested to interact via
currently unknown mechanism with CEs. This interaction could be needed for CE
exchange to occur. This finding is supported by the previous MD simulation which
showed that during lipoprotein binding helix X became buried inside the tunnel
when two CEs were bound to CETP [59].
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5.2 20 ns simulations
The starting structures were constructed to reflect ’random’ initial conditions in
order to better correspond to a biological environment. Hence anacetrapib appeared
in a randomly chosen location outside but in the vicinity of CETP. The purpose was
to observe the diffusion process, namely, how the two particles form a complex. In
addition, the aim was to examine the existence of a long-range force that could assist
the diffusion. With the aid of these simulations it would be possible to evaluate the
consistency of the results. The final goal was to evaluate the interactions between
anacetrapib and the concave surface of CETP and moreover, to see the possible
effects of the drug to the conformation of helix X.
5.2.1 Driving force between CETP and anacetrapib
The equilibration process of each system can be observed from the RMSD profiles
(without water molecules) plotted as a function of time in Figure 5.5. It is apparent
that structures S1-helix, S2-1nm and S3-2nm do not deviate considerably from the
corresponding X-ray structures whereas the last three systems experience fluctuations
between 0.25 and 0.65 nm. The fluctuations are caused by the wandering of the
drug around CETP which can be noticed from the spatial density maps presented
in Figure 5.7. Wandering as well as the rotation explain the changes evident in
the RMSD profiles of the drug. The radii of gyration fluctuated between 3.33 and
3.54 nm, see Figure 5.6.
The reason behind the wandering is the distance between the particles. The
distance ranged from 1 to 2 nm in the first three and from 3 to 4 nm in the last
three simulations. It seems that the change between distances 2 and 3 nm weakens
considerably the van der Waals- (LJ potential) as well as the electrostatic (Coulombic)
interactions between the particles. As can be observed from the spatial density maps
presented in Figure 5.7, the movement of the drug is highly similar in S1-helix,
S2-1nm and S3-2nm where anacetrapib moves at the N-terminal tunnel opening
mainly around residues Arg197, Ser431, Lysh432, Gly433, Ser435 and Hisb462.
These residues are in good agreement with the results obtained from molecular
docking concerning especially the ligand location presented with red, see Figure 4.1.
Concerning the simulations S4-3nm, S5-4nm and S6-convex, it is apparent that the
strength of interactions is weak, since the drug wanders randomly around the protein.
A closer inspection reveals that in S4-3nm anacetrapib ends up at 15 nm distance
from CETP whereas in S5-4nm it settles in the vicinity of residues Glu155 and
Gln161 located at the N-terminal end. In S6-convex anacetrapib reciprocates until it
ends up in the proximity of the C-terminal end.
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(a) S1-helix (b) S2-1nm
(c) S3-2nm (d) S4-3nm
(e) S5-4nm (f) S6-convex
Figure 5.5: RMSD profiles of whole systems (blue) listed in table 4.1 and anacetrapib
(black) molecule for the MD simulations performed for 20 ns.
5. Results and discussion 59
Figure 5.6: Radius of gyration profiles of MD simulations performed for 20 ns.
In addition to distance, the water phase between the particles as well as the effect
of protein’s charge neutralizing ions could weaken the interactions between them.
These suggestions are supported by the interaction energies calculated between CETP
and anacetrapib, see table 5.1 and Figure 5.8. Table 5.1 presents the interactions
energies averaged over the course of simulations. It is apparent that in S1-helix,
S2-1nm and S3-2nm the main force to drive the diffusion process is the weak van der
Waals interaction whereas in S4-3nm, S5-4nm and S6-convex both van der Waals
and electrostatic interaction forces have remarkably diminished. It seems that in
S5-4nm and S6-convex anacetrapib does not interact with CETP through van der
Waals interactions until 2 nm proximity. Another reason responsible for the above
findings is the simulation time since 20 ns may not be long enough time to reliably
interpret the results.
Table 5.1: Average interaction energies between CETP and anacetrapib. The domi-
nant type of interaction is either weak van der Waals (Evdw) interaction or
electrostatic (Eelectrostatic) interaction.
Simulation Evdw (kJ/mol) Eelectrostatic (kJ/mol)
S1-helix -105.7 -30.0
S2-1nm -117.8 -18.4
S3-2nm -115.8 -13.7
S4-3nm 0 0
S5-4nm -38.4 -1.7
S6-convex -4.5 -0.1
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(a) S1-helix (b) S2-1nm
(c) S3-2nm (d) S4-3nm
(e) S5-4nm (f) S6-convex
Figure 5.7: Spatial density maps for anacetrapibs. The map is colored with gray revealing
the movement of the drug outside the lipid binding pocket of CETP.
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(a) S1-helix (b) S2-1nm
(c) S3-2nm (d) S4-3nm
(e) S5-4nm (f) S6-convex
Figure 5.8: Van der Waals and electrostatic interaction energies between CETP and
anacetrapib in MD simulations performed for 20 ns.
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The concept of thermal energy (kBT ) can be connected with the above mentioned
interactions. Basically, thermal energy is the sum of the kinetic energies of all the
atoms in a system. It originates from the individually random, disordered motion of
particles. Thermal energy equals -2.6 kJ mol−1 in the simulation temperature (310 K)
where kB represents the Boltzmann constant. When this value is compared with the
results presented in table 5.1 it is noticed that thermal energy is responsible for the
movement of anacetrapib in S4-3nm, S5-4nm and S6-convex until 2 nm proximity
with the protein, see Figure 5.8. As a consequence, anacetrapib wanders randomly
around the protein without interacting with it.
Altogether, the affinity of anacetrapib towards the concave surface of CETP is
evident taking the distance between the particles into consideration. With too large
distances the movement of the drug is dominated by thermal energy resulting in
disordered motion. In addition, the findings highlight the importance of electrostatic
and van der Waals interactions between the drug and the protein in the formation of
inhibitor-CETP complexes. The remaining question is how the attraction between the
particles could be ensured in order to secure the interactions. Otherwise anacetrapib
may experience random motion and may not be suitable for CETP inhibition
purposes.
5.2.2 Interactions between helix X and anacetrapib
Residual RMS fluctuations for each simulation presented in Figure 5.9 indicate high
mobility and increased B-factors in the hinge region of helix X as well as in the
loops (marked with omegas) located at the N- and C-terminal ends. When these
results are compared with the RMSFs of longer simulations shown in Figure 5.4 it is
explicit that the results are similar. Additionally, equivalent regions were observed to
experience fluctuations regarding the PCA method (data not shown). These results
verify the previously suggested structural elasticity of CETP and its ability to bind
lipoproteins with varying curvatures.
As presented, the significant conformational fluctuations of helix X were observed
in the 200 ns simulations. In accordance with these findings, similar results were
discerned regarding the shorter simulations since helix X was noticed to fluctuate
between turn and 310-helix in S1-helix, S2-1nm and S3-2nm, see appendix A.2.
Anacetrapib was noticed to move at the N-terminal opening which indicates that
the secondary structure changes may be induced by the drug. Based on the above
findings, it is tempting to speculate the mechanisms of the drug related to CETP
inhibition. As it seems that the drug stays at the N-terminal opening, it is possible
that it could prevent the transfer of lipids through the closure of the corresponding
tunnel opening. Secondly, the possible staying at the tunnel opening could prevent
the binding of PLs onto the surface of a lipoprotein. This could hinder the complex
5. Results and discussion 63
Figure 5.9: Residual RMS fluctuations of MD simulations performed for 20 ns. The peaks
indicate the regions of CETP that fluctuated the most during the simulations.
These regions are found in the loops marked with omegas as well as in the
residues corresponding to helix X.
formation between CETP and a lipoprotein particle further reducing the ability of
CETP to transfer neutral lipids.
The MD simulations performed for 200 ns suggested that anacetrapib could
induce changes to the secondary structure of helix X when it is transferred to the
hydrophobic tunnel of CETP. The visualization of the simulation trajectories of
the 20 ns simulations revealed that when the drug moved at the N-terminal tunnel
opening, the trifluoromethyl- and methylene groups of the drug oriented close to
each other, see Figure 5.10. This indicates that the drug aligns itself to a tighter
conformation suggesting a possible movement into the tunnel. Hence anacetrapib
could prefer to interact with helix X as well as with PLs from the hydrophobic cavity.
The suggested movement is supported by the lack of hydrogen bonds between the
protein and the drug. Anacetrapib was noticed to form separate hydrogen bonds
with the residues locating at the N-terminal opening in S1-helix, S2-1nm and S3-2nm.
This implies a weak binding of the drug to CETP since when a new bond was formed,
the previous one was broken. This implies an unobstructed movement of the drug.
However, the binding affinity may have been affected by the simulation time which
may not be long enough to fully confirm these propositions.
Despite the promising results observed in this study, several issues concerning the
structure-function relationship of PLs and helix X as well as the interactions between
anacetrapib, CETP and different lipoprotein particles require further investigations.
Specifically the functions of helix X and PLs during lipoprotein binding and exchange
of lipids are of great importance due to their essential roles in these processes.
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(a) (b)
Figure 5.10: Snaphots from MD simulations performed for 20 ns. a) Snapshot of anace-
trapib at the N-terminal tunnel opening. b) Anacetrapib rotated for 90◦ from
a). The snapshot reveals the proximity of trifluoromethyl- and methylene
groups from each other.
Additionally, attention should be paid to the interactions between helix X and CEs
in order to explain how CETP can exchange PLs but not CEs or TGs in the absence
of helix X. The novel molecular agent anacetrapib developed for CETP inhibition
purposes could have a central role in all of the above mentioned interactions and hence
it is crucial to continue the research related to it. Both anacetrapib and torcetrapib
have previously been reported to increase the binding affinity of CETP towards
lipoproteins and to inhibit the exchange of lipids [70, 73]. However, the precise
mechanisms behind the increased binding affinity as well as inhibition require further
clarification and therefore the research could be extended to involve a lipoprotein
particle in the simulations. The ultimate goal in the future is to combine computer
simulations and experimental studies to better understand the structure-function
relationship of the HDL-CETP-anacetrapib complex.
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6. CONCLUSIONS
The purpose of this work was to study the interactions between CETP and anacetrapib
with atomistic molecular dynamics simulations. In addition, attention was paid to
the structure-function relationship of PLs and helix X. A total of ten different
simulation systems were constructed. They can be divided into two groups based
on their starting configurations and simulation times. The first group consisted of
four systems where the drug molecule was placed inside the lipid binding pocket
of the protein. Each of these systems were simulated for 200 ns. In the second
group the drug was placed outside but in the vicinity of the hydrophobic pocket to
reflect ’random’ initial conditions and hence to better correspond to the biological
environment. These systems were simulated for 20 ns. Previously atomic scale
simulations have been used in the studies concerning CETP and its functions but all
of them have focused on the investigation of interactions between the protein and a
lipoprotein particle ignoring the effects of the drug.
The focus of this work is on the conformational changes experienced by helix X
and PLs during the simulations as well as on the effects of anacetrapib related to
these changes. Additionally, the aim was to examine the diffusion process between
the protein and the drug. Several clinical trials have shown that anacetrapib is able
to inhibit the lipid transfer functions of CETP and as a consequence, to increase the
level of HDL-C and to decrease the level of LDL-C [7]. The cholesterol level changes
of this kind correlate with a reduced risk of cardiovascular diseases. Despite these
promising results, the precise inhibitory mechanism of the drug still needs elucidation.
Nevertheless, it has been proposed that the drug increases the binding affinity
between CETP and different lipoprotein particles [70]. In addition, anacetrapib has
been suggested either to hinder the binding or the detachment of the protein from
lipoprotein surfaces thus preventing the lipid transfer [70]. This work attempts to
clarify the mechanisms behind these functions as well as to characterize the effects
of anacetrapib on the capability of CETP to transport and exchange neutral lipids.
The results obtained in this study point towards the important roles of helix X and
PLs related to the process of neutral lipid exchange. These structures were noticed to
experience considerable conformational fluctuations induced by anacetrapib. Due to
this, the results emphasize the importance of the drug in regulating the functions of
these structures and pave the way for the speculation about the capability of the drug
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to inhibit CETP. However, it is important to notice that the simulations excluded
a lipoprotein particle, and hence these results are only suggestive. Nevertheless,
on the basis of the simulations, the affinity between the drug and the protein was
evident when the distance between the particles is taken into consideration. In
addition to distance, the results highlighted the importance of electrostatic and van
der Waals interactions in the diffusion process. The remaining question is how the
affinity could be ensured in order to secure the interactions between the particles.
Otherwise anacetrapib may experience random motion and may not be suitable for
CETP inhibition purposes. Despite the promising results observed in this study,
additional simulations including the complete lipoprotein-CETP-anacetrapib complex
are required to further clarify the structure-function relationships of helix X and PLs
as well as the inhibitory mechanism of the drug.
This work is mostly pioneering research concerning the interactions between
CETP and anacetrapib and thus paves the way to extend the scope of computational
studies to gain a much deeper understanding concerning the inhibition of CETP. It
is important to extend the research to involve an HDL particle in the simulations in
order to better clarify the mechanisms behind the inhibitory function of the drug as
well as the interactions between helix X and PLs needed for the lipid exchange to
occur. The ultimate goal in the future is to combine the computer simulations and
experimental studies to validate the complicated interactions between the complete
HDL-CETP-anacetrapib complex. The novel understanding could be used to develop
new molecular agents to fight against the progression of cardiovascular diseases since
the existing medicines are not able to prevent all cardiovascular events. Overall, this
work gives a solid foundation for future research projects related to anacetrapib.
67
REFERENCES
[1] K. Kristiansson. Genetics of cardiovascular disease: A candidate gene study
of USF1. 8, 2008.
[2] P. Libby. Atherosclerosis: The new view. Scientific American, 286:46–55,
2002.
[3] Suomen Syda¨nliitty ry. Suositus veren kolesteroli-ja rasva-arvoista.
http://arkisto.sydanliitto.fi/kaikki_sydamesta/kolesteroli/fi_
FI/suositus/, 2005. Retrieved on July 26, 2011.
[4] A.J. Lusis. Atherosclerosis. Nature, 407:233–241, 2000.
[5] A.R. Tall. Plasma cholesteryl ester transfer protein. Journal of Lipid Research,
34:1255–1274, 1993.
[6] P.J. Barter, M. Caulfield, M. Eriksson, S.M. Grundy, J.J.P.
Kastelein, M. Komajda, J. Lopez-Sendon, L. Mosca, J.C. Tardif,
D.D. Waters, C.L. Shear, J.H. Revkin, K.A. Buhr, M.R. Fisher,
A.R. Tall, and B. Brewer. Effects of torcetrapib in patients at high risk for
coronary events. New England Journal of Medicine, 357:2109–2122, 2007.
[7] C.P. Cannon, S. Shah, H.M. Dansky, M. Davidson, E.A. Brinton,
A.M. Gotto Jr, M. Stepanavage, S.X. Liu, P. Gibbons, T.B. Ashraf,
J. Zafarino, Y. Mitchel, and P. Barter. Safety of anacetrapib in patients
with or at high risk for coronary heart disease. New England Journal of
Medicine, 363:2406–2415, 2010.
[8] Syda¨n- ja verisuonisairauksien ja diabeteksen asiantuntijaryhma¨n raportti 2008.
Kansanterveyslaitoksen julkaisuja B, pages 1–62, 2008.
[9] Cardiovascular disease foundation. http://www.cvdf.org/default.
aspx. Retrieved on July 8, 2011.
[10] P. Barter, J. Kastelein, A. Nunn, and R. Hobbs. High density lipopro-
teins (HDLs) and atherosclerosis; The unanswered questions. Atherosclerosis,
168:195–211, 2003.
[11] P. Natarajan, K.K. Ray, and C.P. Cannon. High-density lipoprotein and
coronary heart disease: Current and future therapies. Journal of the American
College of Cardiology, 55:1283–1299, 2010.
REFERENCES 68
[12] Suomen Syda¨nliitty ry. Kolesterolia alentavat la¨a¨kkeet. http://www.
sydanliitto.fi/kolesterolia-alentavat-laakkeet, 2005. Retrieved on
September 6, 2011.
[13] R.J. Chilton. Pathophysiology of coronary heart disease: A brief review.
Journal of the American Osteopathic Association, 104:S5–S8, 2004.
[14] P. Libby. Current concepts of the pathogenesis of the acute coronary syn-
dromes. Circulation, 104:364–372, 2001.
[15] K. Laitinen. Mitka¨ ovat statiinien haitta- ja yhteisvaikutukset? Apteekkari,
8:18–19, 2004.
[16] S. O’Sullivan. Statins: A review of benefits and risks. Trinity Student Medical
Journal, 8:52–56, 2007.
[17] P. Libby, P.M. Ridker, and A. Maseri. Inflammation and atherosclerosis.
Circulation, 105:1135–1143, 2002.
[18] D. Polk and P.K. Shah. Cholesterol ester transfer protein (CETP) and
atherosclerosis. Drug Discovery Today: Therapeutic Strategies, 4:137–145, 2007.
[19] T.N. Tulenko and A.E. Sumner. The physiology of lipoproteins. Journal
of nuclear cardiology, 9:638–649, 2002.
[20] M.H. Davidson and R.S. Rosenson. Novel targets that affect high-density
lipoprotein metabolism: The next frontier. The American journal of cardiology,
104:52E–57E, 2009.
[21] G.S. Berenson, S.R. Srinivasan, B. Weihang, W.P. Newman, R.E.
Tracy, and W.A. Wattigney. Association between multiple cardiovascular
risk factors and atherosclerosis in children and young adults. The New England
journal of medicine, 338:1650–1656, 1998.
[22] Terveyskirjasto Duodecim. Kolesteroli. http://www.terveyskirjasto.
fi/terveyskirjasto/tk.koti?p_artikkeli=dlk00035, 2010. Retrieved on
September 6, 2011.
[23] Patient UK Newspaper. Preventing cardiovascular diseases. http://www.
patient.co.uk/pdf/pilsL82.pdf, 2010. Retrieved on July 8, 2011.
[24] J. Huttunen, A. Kesa¨niemi, P. Kovanen, T. Kuusi, M. Laakso,
A. Lehtonen, T. Miettinen, P. Pentika¨inen, K. Pyo¨ra¨la¨, A. Reuna-
nen, J. Salmi, M. Salo, T. Strandberg, M. Syva¨nne, M.R. Taskinen,
REFERENCES 69
M. Tikkanen, R. Tilvis, A. Tuomi, M. Uusitupa, and J. Viikari. Li-
pidiaineenvaihdunnan ha¨irio¨t. Orion.
[25] T.J. Wang, M.J. Pencina, S.L. Booth, P.F. Jacques, E. Ingelsson,
K. Lanier, E.J. Benjamin, R.B. D’Agostino, M. Wolf, and R.S.
Vasan. Vitamin D deficiency and risk of cardiovascular disease. Circula-
tion, 117:503–511, 2008.
[26] E.D. Michos, J.P. Reis, and M.L. Melamed. Vitamin D status and
cardiovascular health: A 2009 update. The open clinical chemistry journal, 3:
51–59, 2010.
[27] C.J. Lavie, J.H. Lee, and R.V. Milani. Vitamin D and cardiovascular
disease: Will it live up to its hype? Journal of the American College of
Cardiology, 58:1547–1556, 2011.
[28] J.B. German, J.T. Smilowitz, and A.M. Zivkovic. Lipoproteins: When
size really matters. Current opinion in colloid & interface science, 11:171–183,
2006.
[29] H.K. Walker, W.D. Hall, and J.W. Hurst. Clinical methods. The history,
physical, and laboratory examinations. Butterworths, Boston, 3rd edition, 1990.
[30] T. Hevonoja, M.O. Pentika¨inen, M.T Hyvo¨nen, P.T. Kovanen, and
M. Ala-Korpela. Structure of low density lipoprotein (LDL) particles: Basis
for understanding molecular changes in modified LDL. Biochimica et Biophysica
Acta (BBA)-Molecular and Cell Biology of Lipids, 1488:189–210, 2000.
[31] T. Murtola, T.A. Vuorela, M.T. Hyvo¨nen, S.J. Marrink, M. Kart-
tunen, and I. Vattulainen. Low density lipoprotein: Structure, dynamics,
and interactions of apoB-100 with lipids. Soft Matter, 7:8135–8141, 2011.
[32] S.M. Grundy. Role of low-density lipoproteins in atherogenesis and develop-
ment of coronary heart disease. Clinical chemistry, 41:139–146, 1995.
[33] O.G. Mouritsen. Life-as a matter of fat. Springer Berlin, Germany, 2005.
[34] W.P. Castelli. Cholesterol and lipids in the risk of coronary artery disease–the
Framingham Heart Study. The Canadian journal of cardiology, 4:5A, 1988.
[35] J.D. Curb, R.D. Abbott, B.L. Rodriguez, K. Masaki, R. Chen, D.S.
Sharp, and A.R. Tall. A prospective study of HDL-C and cholesteryl ester
transfer protein gene mutations and the risk of coronary heart disease in the
elderly. Journal of lipid research, 45:948–953, 2004.
REFERENCES 70
[36] R. Vikstedt. The role of phospholipid transfer protein and cholesteryl ester
transfer protein in reverse cholesterol transport. 2009.
[37] C.G. Santos-Gallego, B. Ibanez, and J.J. Badimon. HDL-cholesterol:
Is it really good? Differences between apoA-I and HDL. Biochemical pharma-
cology, 76:443–452, 2008.
[38] H. Saito, S. Lund-Katz, and M.C. Phillips. Contributions of domain
structure and lipid interaction to the functionality of exchangeable human
apolipoproteins. Progress in Lipid Research, 43:350–380, 2004.
[39] T. Vuorela, A. Catte, P.S. Niemela¨, A. Hall, M.T. Hyvo¨nen, S.J.
Marrink, M. Karttunen, and I. Vattulainen. Role of lipids in spheroidal
high density lipoproteins. PLoS Computational Biology, 6:e1000964, 2010.
[40] A. Catte, J.C. Patterson, D. Bashtovyy, M.K. Jones, F. Gu, L. Li,
A. Rampioni, D. Sengupta, T. Vuorela, P. Niemela¨, S.J. Marrink,
I. Vattulainen, and J.P. Segrest. Structure of spheroidal HDL particles
revealed by combined atomistic and coarse-grained simulations. Biophysical
journal, 94:2306–2319, 2008.
[41] C. Bruce, R.A. Chouinard Jr, and A.R. Tall. Plasma lipid transfer
proteins, high-density lipoproteins, and reverse cholesterol transport. Annual
review of nutrition, 18:297–330, 1998.
[42] J.P. Segrest, M.K. Jones, A.E. Klon, C.J. Sheldahl, M. Hellinger,
H. De Loof, and S.C. Harvey. A detailed molecular belt model for
apolipoprotein AI in discoidal high density lipoprotein. Journal of Biological
Chemistry, 274:31755–31758, 1999.
[43] A.Y. Shih, P.L. Freddolino, A. Arkhipov, and K. Schulten. Assem-
bly of lipoprotein particles revealed by coarse-grained molecular dynamics
simulations. Journal of structural biology, 157:579–592, 2007.
[44] A.Y. Shih, S.G. Sligar, and K. Schulten. Maturation of high-density
lipoproteins. Journal of The Royal Society Interface, 6:863–871, 2009.
[45] R.A. Silva, R. Huang, J. Morris, J. Fang, E.O. Gracheva, G. Ren,
A. Kontush, W.G. Jerome, K.A. Rye, and W.S. Davidson. Structure
of apolipoprotein AI in spherical high density lipoproteins of different sizes.
Proceedings of the National Academy of Sciences, 105:12176–12181, 2008.
REFERENCES 71
[46] L. Yetukuri, S. So¨derlund, A. Koivuniemi, T. Seppa¨nen-Laakso, P.S.
Niemela¨, M. Hyvo¨nen, M.R. Taskinen, I. Vattulainen, M. Jauhi-
ainen, and M. Oresˇicˇ. Composition and lipid spatial distribution of HDL
particles in subjects with low and high HDL-cholesterol. Journal of lipid
research, 51:2341–2351, 2010.
[47] E.A. Kaperonis, C.D. Liapis, J.D. Kakisis, D. Dimitroulis, and V.G.
Papavassiliou. Inflammation and atherosclerosis. European journal of vascular
and endovascular surgery, 31:386–393, 2006.
[48] L. Lind. Circulating markers of inflammation and atherosclerosis. Atheroscle-
rosis, 169:203–214, 2003.
[49] K. Ikewaki, D.J. Rader, T. Sakamoto, M. Nishiwaki, N. Wakimoto,
J.R. Schaefer, T. Ishikawa, T. Fairwell, L.A. Zech, H. Nakamura,
M. Nagano, and H.B. Brewer. Delayed catabolism of high density lipopro-
tein apolipoproteins AI and A-II in human cholesteryl ester transfer protein
deficiency. Journal of Clinical Investigation, 92:1650–1658, 1993.
[50] M.L. Brown, A. Inazu, C.B. Hesler, L.B. Agellon, C. Mann, M.E.
Whitlock, Y.L. Marcel, R.W. Milne, J. Koizumi, H. Mabuchi,
R. Takeda, and A.R. Tall. Molecular basis of lipid transfer protein de-
ficiency in a family with increased high-density lipoproteins. Nature, 342:
448–451, 1989.
[51] S. Zhong, D.S. Sharp, J.S. Grove, C. Bruce, K. Yano, J.D. Curb,
and A.R. Tall. Increased coronary heart disease in Japanese-American men
with mutation in the cholesteryl ester transfer protein gene despite increased
HDL levels. Journal of Clinical Investigation, 97:2917–2923, 1996.
[52] P.J. Barter, H.B. Brewer, M.J. Chapman, C.H. Hennekens, D.J.
Rader, and A.R. Tall. Cholesteryl ester transfer protein: A novel target for
raising HDL and inhibiting atherosclerosis. Arteriosclerosis, thrombosis, and
vascular biology, 23:160–167, 2003.
[53] M.J. Chapman, W.L. Goff, M. Guerin, and A. Kontush. Cholesteryl
ester transfer protein: At the heart of the action of lipid-modulating therapy
with statins, fibrates, niacin, and cholesteryl ester transfer protein inhibitors.
European Heart Journal, 31:149–164, 2010.
[54] P. Roy, R. MacKenzie, T. Hirama, XC Jiang, P. Kussie, A. Tall,
E. Rassart, and R. Milne. Structure-function relationships of human
REFERENCES 72
cholesteryl ester transfer protein: Analysis using monoclonal antibodies. Journal
of lipid research, 37:22–34, 1996.
[55] X. Qiu, A. Mistry, M.J. Ammirati, B.A. Chrunyk, R.W. Clark,
Y. Cong, J.S. Culp, D.E. Danley, T.B. Freeman, K.F. Geoghegan,
et al. Crystal structure of cholesteryl ester transfer protein reveals a long
tunnel and four bound lipid molecules. Nature structural & molecular biology,
14:106–113, 2007.
[56] A.J. Lusis, S. Zollman, R.S. Sparkes, I. Klisak, T. Mohandas,
D. Drayna, and R.M. Lawn. Assignment of the human gene for cholesteryl
ester transfer protein to chromosome 16q12-16q21. Genomics, 1:232–235, 1987.
[57] Protein data bank. Crystal structure of cholesteryl ester transfer pro-
tein. http://www.pdb.org/pdb/results/results.do?outformat=&qrid=
EDE455F1&tabtoshow=Current. Retrieved on July 20, 2011.
[58] Z. Yuan, T.L. Bailey, and R.D. Teasdale. Prediction of protein B-factor
profiles. Proteins: Structure, Function, and Bioinformatics, 58:905–912, 2005.
[59] A. Koivuniemi, T. Vuorela, P.T. Kovanen, I. Vattulainen, and M.T.
Hyvo¨nen. Lipid exchange mechanism of the cholesteryl ester transfer protein
clarified by atomistic and coarse-grained simulations. PLoS computational
biology, 8, 2012.
[60] C. Bruce, L.J. Beamer, and A.R. Tall. The implications of the structure
of the bactericidal/permeability-increasing protein on the lipid-transfer function
of the cholesteryl ester transfer protein. Current opinion in structural biology,
8:426–434, 1998.
[61] N.M. Pattnaik and D.B. Zilversmit. Interaction of cholesteryl ester ex-
change protein with human plasma lipoproteins and phospholipid vesicles.
Journal of Biological Chemistry, 254:2782–2786, 1979.
[62] R.B. Weinberg, V.R. Cook, J.B. Jones, P. Kussie, and A.R. Tall.
Interfacial properties of recombinant human cholesterol ester transfer protein.
Journal of Biological Chemistry, 269:29588–29591, 1994.
[63] R.E. Morton and D.J. Greene. The surface cholesteryl ester content of
donor and acceptor particles regulates CETP. Journal of lipid research, 44:
1364–1372, 2003.
[64] B.F. Asztalos, K.V. Horvath, K. Kajinami, C. Nartsupha, C.E. Cox,
M. Batista, E.J. Schaefer, A. Inazu, and H. Mabuchi. Apolipoprotein
REFERENCES 73
composition of HDL in cholesteryl ester transfer protein deficiency. Journal of
lipid research, 45:448–455, 2004.
[65] M.H. Davidson. Update on CETP inhibition. Journal of Clinical Lipidology,
4:394–398, 2010.
[66] R.W. Clark, R.B. Ruggeri, D. Cunningham, and M.J. Bamberger.
Description of the torcetrapib series of cholesteryl ester transfer protein in-
hibitors, including mechanism of action. Journal of lipid research, 47:537–552,
2006.
[67] A.R. Tall. Functions of cholesterol ester transfer protein and relationship to
coronary artery disease risk. Journal of Clinical Lipidology, 4:389–393, 2010.
[68] S. Wang, L. Deng, R.W. Milne, and A.R. Tall. Identification of a
sequence within the c-terminal 26 amino acids of cholesteryl ester transfer
protein responsible for binding a neutralizing monoclonal antibody and neces-
sary for neutral lipid transfer activity. Journal of Biological Chemistry, 267:
17487–17490, 1992.
[69] S. Wang, X. Wang, L. Deng, E. Rassart, R.W. Milne, and A.R. Tall.
Point mutagenesis of carboxyl-terminal amino acids of cholesteryl ester transfer
protein. opposite faces of an amphipathic helix important for cholesteryl ester
transfer or for binding neutralizing antibody. Journal of Biological Chemistry,
268:1955–1959, 1993.
[70] D. Masson. Anacetrapib, a cholesterol ester transfer protein (CETP) inhibitor
for the treatment of atherosclerosis. Current opinion in investigational drugs
(London, England: 2000), 10:980–987, 2009.
[71] American Medical Association. Statement on a nonproprietary name
adopted by the USAN council: Anacetrapib. http://www.ama-assn.org/
ama1/pub/upload/mm/365/anacetrapib.pdf, 2007. Retrieved on July 25,
2011.
[72] C.J. Smith, A. Ali, M.L. Hammond, H. Li, Z. Lu, J. Napolitano,
G.E. Taylor, C.F. Thompson, M.S. Anderson, Y. Chen, S.S. Eve-
land, Q. Guo, S.A. Hyland, D.P. Milot, C.P. Sparrow, S.D. Wright,
A.M. Cumiskey, M. Latham, L.B. Peterson, R. Rosa, J.V. Pivnichny,
X. Tong, S.S. Xu, and P.J. Sinclair. Biphenyl-substituted oxazolidinones
as cholesteryl ester transfer protein inhibitors: Modifications of the oxazo-
lidinone ring leading to the discovery of anacetrapib. Journal of medicinal
chemistry, 54:4880–4895, 2011.
REFERENCES 74
[73] R. Gurfinkel and T.R. Joy. Anacetrapib: Hope for CETP inhibitors?
Cardiovascular therapeutics, 29:327–339, 2010.
[74] H. Okamoto, F. Yonemori, K. Wakitani, T. Minowa, K. Maeda,
and H. Shinkai. A cholesteryl ester transfer protein inhibitor attenuates
atherosclerosis in rabbits. Nature, 406:203–207, 2000.
[75] M. Ranalletta, K.K. Bierilo, Y. Chen, D. Milot, Q. Chen, E. Tung,
C. Houde, N.H. Elowe, M. Garcia-Calvo, G. Porter, S. Eveland,
B. Frantz-Wattley, M. Kavana, G. Addona, P. Sinclair, C. Sparrow,
E.A. O’Neill, K.S. Koblan, A. Sitlani, B. Hubbard, and T.S. Fisher.
Biochemical characterization of cholesteryl ester transfer protein inhibitors.
Journal of lipid research, 51:2739–2752, 2010.
[76] S. Kumar, E.Y. Tan, G. Hartmann, Z. Biddle, A.J. Bergman, J. Dru,
J.Z. Ho, A.N. Jones, S.J. Staskiewicz, M.P. Braun, B. Karanam,
D.C. Dean, I.N. Gendrano, M.W. Graves, J.A. Wagner, and R. Kr-
ishna. Metabolism and excretion of anacetrapib, a novel inhibitor of the
cholesteryl ester transfer protein, in humans. Drug Metabolism and Disposition,
38:474–483, 2010.
[77] E.Y. Tan, G. Hartmann, Q. Chen, A. Pereira, S. Bradley, G. Doss,
A.S. Zhang, J.Z. Ho, M.P. Braun, D.C. Dean, W. Tang, and S. Ku-
mar. Pharmacokinetics, metabolism, and excretion of anacetrapib, a novel
inhibitor of the cholesteryl ester transfer protein, in rats and rhesus monkeys.
Drug Metabolism and Disposition, 38:459–473, 2010.
[78] R. Krishna, A.J. Bergman, B. Jin, A. Garg, B. Roadcap, R. Chiou,
J. Dru, J. Cote, T. Laethem, R.W. Wang, V. Didolkar, E. Vets,
K. Gottesdiener, and J.A. Wagner. Assessment of the CYP3A-mediated
drug interaction potential of anacetrapib, a potent cholesteryl ester transfer
protein (CETP) inhibitor, in healthy volunteers. The Journal of Clinical
Pharmacology, 49:80–87, 2009.
[79] R. Krishna, M.S. Anderson, A.J. Bergman, B. Jin, M. Fallon,
J. Cote, K. Rosko, C. Chavez-Eng, R. Lutz, D.M. Bloomfield,
M. Gutierrez, J. Doherty, F. Bieberdorf, J. Chodakewitz, K.M
Gottesdiener, and J.A. Wagner. Effect of the cholesteryl ester transfer pro-
tein inhibitor, anacetrapib, on lipoproteins in patients with dyslipidaemia and
on 24-h ambulatory blood pressure in healthy individuals: Two double-blind,
randomised placebo-controlled phase I studies. The Lancet, 370:1907–1914,
2007.
REFERENCES 75
[80] D. Bloomfield, G.L. Carlson, A. Sapre, D. Tribble, J.M. McKenney,
T.W. Littlejohn III, C.M.C. Sisk, Y. Mitchel, and R.C. Pasternak.
Efficacy and safety of the cholesteryl ester transfer protein inhibitor anacetrapib
as monotherapy and coadministered with atorvastatin in dyslipidemic patients.
American heart journal, 157:352–360, 2009.
[81] C.P. Cannon, H.M. Dansky, M. Davidson, A.M. Gotto Jr, E.A. Brin-
ton, A.L. Gould, M. Stepanavage, S.X. Liu, S. Shah, J. Rubino,
P. Gibbons, A. Hermanowski-Vosatka, B. Binkowitz, Y. Mitchel,
and P. Barter. Design of the DEFINE trial: Determining the EFficacy and
tolerability of CETP INhibition with anacEtrapib. American heart journal,
158:513–519, 2009.
[82] L. Yvan-Charvet, F. Matsuura, N. Wang, M.J. Bamberger,
T. Nguyen, F. Rinninger, X.C. Jiang, C.L. Shear, and A.R. Tall.
Inhibition of cholesteryl ester transfer protein by torcetrapib modestly in-
creases macrophage cholesterol eﬄux to HDL. Arteriosclerosis, thrombosis,
and vascular biology, 27:1132–1138, 2007.
[83] L. Yvan-Charvet, J. Kling, T. Pagler, H. Li, B. Hubbard, T. Fisher,
C.P. Sparrow, A.K. Taggart, and A.R. Tall. Cholesterol eﬄux potential
and anti-inflammatory properties of high-density lipoprotein after treatment
with niacin or anacetrapib. Arteriosclerosis, thrombosis, and vascular biology,
30:1430–1438, 2010.
[84] M.E. Brousseau, E.J. Schaefer, M.L. Wolfe, L.A.T. Bloedon, A.G.
Digenio, R.W. Clark, J.P. Mancuso, and D.J. Rader. Effects of an
inhibitor of cholesteryl ester transfer protein on HDL cholesterol. New England
Journal of Medicine, 350:1505–1515, 2004.
[85] R.W. Clark, T.A. Sutfin, R.B. Ruggeri, A.T. Willauer, E.D. Sugar-
man, G. Magnus-Aryitey, P.G. Cosgrove, T.M. Sand, R.T. Wester,
J.A. Williams, M.E. Perlman, and M.J. Bamberger. Raising high-
density lipoprotein in humans through inhibition of cholesteryl ester transfer
protein. Arteriosclerosis, thrombosis, and vascular biology, 24:490–497, 2004.
[86] S.E. Nissen, J.C. Tardif, S.J. Nicholls, J.H. Revkin, C.L. Shear, W.T.
Duggan, W. Ruzyllo, W.B. Bachinsky, G.P. Lasala, and E.M. Tuzcu.
Effect of torcetrapib on the progression of coronary atherosclerosis. New England
Journal of Medicine, 356:1304–1316, 2007.
[87] M.L. Bots, F.L. Visseren, G.W. Evans, W.A. Riley, J.H. Revkin,
C.H. Tegeler, C.L. Shear, W.T. Duggan, R.M. Vicari, D.E. Grobbee,
REFERENCES 76
and J.J. Kastelein. Torcetrapib and carotid intima-media thickness in mixed
dyslipidaemia (RADIANCE 2 study): A randomised, double-blind trial. The
Lancet, 370:153–160, 2007.
[88] J.J.P. Kastelein, S.I. van Leuven, L. Burgess, G.W. Evans, J.A.
Kuivenhoven, P.J. Barter, J.H. Revkin, D.E. Grobbee, W.A. Ri-
ley, C.L. Shear, W.T. Duggan, and M.L. Bots. Effect of torcetrapib on
carotid atherosclerosis in familial hypercholesterolemia. New England Journal
of Medicine, 356:1620–1630, 2007.
[89] S.J. Nicholls, E.M. Tuzcu, D.M. Brennan, J.C. Tardif, and S.E. Nis-
sen. Cholesteryl ester transfer protein inhibition, high-density lipoprotein
raising, and progression of coronary atherosclerosis: Insights from ILLUS-
TRATE (investigation of lipid level management using coronary ultrasound
to assess reduction of atherosclerosis by CETP inhibition and HDL elevation).
Circulation, 118:2506–2514, 2008.
[90] L. Xie, J. Li, L. Xie, and P.E. Bourne. Drug discovery using chemical
systems biology: Identification of the protein-ligand binding network to explain
the side effects of CETP inhibitors. PLoS computational biology, 5:e1000387,
2009.
[91] H. Shinkai, K. Maeda, T. Yamasaki, H. Okamoto, and I. Uchida.
bis (2-(acylamino) phenyl) disulfides, 2-(acylamino) benzenethiols, and s-(2-
(acylamino) phenyl) alkanethioates as novel inhibitors of cholesteryl ester
transfer protein. Journal of medicinal chemistry, 43:3566–3572, 2000.
[92] M. Vergeer and E.S.G. Stroes. The pharmacology and off-target effects
of some cholesterol ester transfer protein inhibitors. The American journal of
cardiology, 104:32E–38E, 2009.
[93] G.J. de Grooth, J.A. Kuivenhoven, A.F.H. Stalenhoef, J. de Graaf,
A.H. Zwinderman, J.L. Posma, A. van Tol, and J.J.P. Kastelein.
Efficacy and safety of a novel cholesteryl ester transfer protein inhibitor, JTT-
705, in humans: A randomized phase II dose-response study. Circulation, 105:
2159–2165, 2002.
[94] J.A. Kuivenhoven, G.J. de Grooth, H. Kawamura, A.H. Klerkx,
F. Wilhelm, M.D. Trip, and J.J.P. Kastelein. Effectiveness of inhibition
of cholesteryl ester transfer protein by JTT-705 in combination with pravastatin
in type II dyslipidemia. The American journal of cardiology, 95:1085–1088,
2005.
REFERENCES 77
[95] E.A. Stein, E.S.G. Stroes, G. Steiner, B.M. Buckley, A.M. Capponi,
T. Burgess, E.J. Niesor, D. Kallend, and J.J.P. Kastelein. Safety and
tolerability of dalcetrapib. The American journal of cardiology, 104:82–91,
2009.
[96] Hoffmann-La Roche. A study of ro4607381 in stable coronary heart disease
patients with recent acute coronary syndrome. http://clinicaltrials.gov/
ct2/show/NCT00658515. Retrieved on September 5, 2011.
[97] B. Hess, D. van der Spoel, E. Lindahl, E. Apol, R. Apostolov, H.J.C.
Berendsen, A. van Buuren, P. Bjelkmar, R. van Drunen, A. Feenstra,
G. Groenhof, P. Kasson, P. Larsson, P. Meulenhoff, T. Murtola,
S. Pall, S. Pronk, R. Schulz, M. Shirts, A. Sijbers, and P. Tieleman.
Gromacs user manual version 4.5.4. http://www.gromacs.org, 2010. Retrieved
on September 19, 2011.
[98] T. Schlick. Molecular modeling and simulation: An interdisciplinary guide.
Springer, New York, 2006.
[99] D. Van Der Spoel, E. Lindahl, B. Hess, G. Groenhof, A.E. Mark,
and H.J.C. Berendsen. Gromacs: Fast, flexible, and free. Journal of
computational chemistry, 26:1701–1718, 2005.
[100] R.W. Hockney, S.P. Goel, and J.W. Eastwood. Quiet high-resolution
computer models of a plasma. Journal of Computational Physics, 14:148–158,
1974.
[101] H.J.C. Berendsen and W.F. van Gunsteren. Practical algorithms for
dynamics simulations. Molecular simulation, 1:173–185, 1988.
[102] M.P. Allen and D.J. Tildesley. Computer simulation of liquids. Clarendon
Press, 1999.
[103] H.J.C. Berendsen, J.P.M. Postma, W.F. Van Gunsteren, A. DiNola,
and J.R. Haak. Molecular dynamics with coupling to an external bath. The
Journal of Chemical Physics, 81:3684–3690, 1984.
[104] W.G. Hoover. Canonical dynamics: Equilibrium phase-space distributions.
Physical Review A, 31:1695–1697, 1985.
[105] M. Parrinello and A. Rahman. Polymorphic transitions in single crystals:
A new molecular dynamics method. Journal of Applied Physics, 52:7182–7190,
1981.
REFERENCES 78
[106] A.Y. Toukmaji and J.A. Board. Ewald summation techniques in perspec-
tive: A survey. Computer Physics Communications, 95:73–92, 1996.
[107] P.P. Ewald. Ewald summation. Ann. Phys, 369, 1921.
[108] B. Hess, H. Bekker, H.J.C. Berendsen, and J.G.E.M. Fraaije. LINCS:
A linear constraint solver for molecular simulations. Journal of computational
chemistry, 18:1463–1472, 1997.
[109] V. Kra¨utler, W.F. van Gunsteren, and P.H. Hu¨nenberger. A fast
SHAKE algorithm to solve distance constraint equations for small molecules
in molecular dynamics simulations. Journal of Computational Chemistry, 22:
501–508, 2001.
[110] H.C. Andersen. Rattle: A ”velocity” version of the shake algorithm for
molecular dynamics calculations. Journal of Computational Physics, 52:24–34,
1983.
[111] W.L. Jorgensen, D.S. Maxwell, and J. Tirado-Rives. Development and
testing of the OPLS all-atom force field on conformational energetics and
properties of organic liquids. Journal of the American Chemical Society, 118:
11225–11236, 1996.
[112] O. Trott and A.J. Olson. AutoDock Vina: Improving the speed and
accuracy of docking with a new scoring function, efficient optimization, and
multithreading. Journal of computational chemistry, 31:455–461, 2010.
[113] B.L. Dong, Q.H. Liao, and J. Wei. Docking and molecular dynamics study
on the inhibitory activity of n, n-disubstituted-trifluoro-3-amino-2-propanols-
based inhibitors of cholesteryl ester transfer protein. Journal of Molecular
Modeling, 17:1727–1734, 2010.
[114] W. Humphrey, A. Dalke, and K. Schulten. Vmd: Visual molecular
dynamics. Journal of molecular graphics, 14:33–38, 1996.
[115] G. Vrient. DSSP. http://swift.cmbi.ru.nl/gv/dssp/. Retrieved on
October 7, 2011.
[116] Rizzo Research Lab. MD simulation: Protein in water. http://ringo.ams.
sunysb.edu/index.php/MD_Simulation:_Protein_in_Water. Retrieved on
October 7, 2011.
[117] W. Kabsch and C. Sander. Dictionary of protein secondary structure:
Pattern recognition of hydrogen-bonded and geometrical features. Biopolymers,
22:2577–2637, 1983.
REFERENCES 79
[118] V.N. Maiorov and G.M. Crippen. Significance of root-mean-square devi-
ation in comparing three-dimensional structures of globular proteins. Journal
of Molecular Biology, 235:625–634, 1994.
[119] B. de Groot. Principal component analysis. http://www.mpibpc.mpg.de/
groups/de_groot/compbio1/p4/index.html#intro. Retrieved on October
6, 2011.
[120] A. Chatterjee and A.K. Bothra. Molecular dynamics simulation of An-
giotensin I: Precursor of Angiotensin II. Int. J. Integ. Biol, 9:21–25, 2010.
[121] Z.S. Derewenda, L. Lee, and U. Derewenda. The occurence of CH-O
hydrogen bonds in proteins. Journal of molecular biology, 252:248–262, 1995.
[122] P.B. Balbuena and J.M. Seminario. Molecular dynamics: from classical
to quantum methods, volume 7. Elsevier Science, 1999.
[123] T.V. Bogdan and E.V. Isaeva. Molecular dynamic simulation of the struc-
ture of liquid chlorobenzene, ortho-chlorotoluene and their mixtures. Journal
of Structural Chemistry, 50:640–646, 2009.
80
A. APPENDIX
A.1 Secondary structures of systems simulated for 200 ns
A.1.1 L1-200ns
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Figure A.1: Secondary structure of CETP during the simulation L1-200ns. The secondary
structure does not change greatly during the simulation despite the small
fluctuations. The changes within helix X (residues 461-472) are of great
importance.
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A.1.2 L2-200ns
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Figure A.2: Secondary structure of CETP during the simulation L2-200ns. The secondary
structure does not change greatly during the simulation despite the small
fluctuations. The changes within helix X (residues 461-472) are of great
importance.
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A.1.3 L3-200ns
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Figure A.3: Secondary structure of CETP during the simulation L3-200ns. The secondary
structure does not change greatly during the simulation despite the small
fluctuations. The changes within helix X (residues 461-472) are of great
importance.
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A.1.4 L4-200ns
A. Appendix 90
A. Appendix 91
Figure A.4: Secondary structure of CETP during the simulation L4-200ns. The secondary
structure does not change greatly during the simulation despite the small
fluctuations. The changes within helix X (residues 461-472) are of great
importance.
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A.2 Secondary structures of systems simulated for 20 ns
A.2.1 S1-helix
Figure A.5: Secondary structure of CETP during the simulation S1-helix. The secondary
structure does not change greatly during the simulation despite the small
fluctuations. The changes within helix X (residues 461-472) are of great
importance.
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A.2.2 S2-1nm
Figure A.6: Secondary structure of CETP during the simulation S2-1nm. The secondary
structure does not change greatly during the simulation despite the small
fluctuations. The changes within helix X (residues 461-472) are of great
importance.
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A.2.3 S3-2nm
Figure A.7: Secondary structure of CETP during the simulation S3-2nm. The secondary
structure does not change greatly during the simulation despite the small
fluctuations. The changes within helix X (residues 461-472) are of great
importance.
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A.2.4 S4-3nm
Figure A.8: Secondary structure of CETP during the simulation S4-3nm. The secondary
structure does not change greatly during the simulation despite the small
fluctuations. The changes within helix X (residues 461-472) are of great
importance.
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A.2.5 S5-4nm
Figure A.9: Secondary structure of CETP during the simulation S5-4nm. The secondary
structure does not change greatly during the simulation despite the small
fluctuations. The changes within helix X (residues 461-472) are of great
importance.
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A.2.6 S6-convex
Figure A.10: Secondary structure of CETP during the simulation S6-convex. The sec-
ondary structure does not change greatly during the simulation despite the
small fluctuations. The changes within helix X (residues 461-472) are of
great importance.
